INDEX TO VOLUME 180

Author Index

Abadi, J., 915
Abbott, S., 1361
Abdelhameed, A. A., 1298
Abel, L., 1298
Abernathy, R. A., 1763
Ablashi, D., 1682
Abraham, E., 116
Abrego, P., 1709
Active Bacterial Core Surveillance Team, 1894
Adabayeri, V., 1753
Adachi, J. A., 2053
Adams, D. R., 673
Adams, G. J., 1245
Adams, R. J., 950
Addis, M. F., 1727
Ademowo, O. G., 925
Ades, E., 133
Adimora, A. A., 99
Adler, G., 1407
Adler, S. P., 843
Agnew, D. A., 167
Agosti, J. M., 1064, 2023
Aguero, S. M., 391
Ahmad, M., 862
Aiba, Y., 1374
Akanmori, B. D., 1753
Akatsuka, A., 1374
Akood, M., 1738
Alberici, F., 1018
ALBI (ANRS 070) Study Group, 351
Alcocer, E., 929
Alcorn, T. M., 1018
Alegria, S., 1709
Alessi, M., 2074
Alexander, L., 1790
Allard, R., 1803
Allegra, L., 2074
Almeida, R. P., 1731, 1735
Almera, R., 2081
Alonso, A., 614
Alrajhi, A. A., 1738
Altekruse, S. F., 1214
Alvelo, J. I., 1503
Alves-Oliveira, L. F., 1665
Alvord, W. G., 586
Ambinder, R. F., 824
Amin, A., 1751
Ancuta, P., 1057
Anders, E. M., 2009
Anderson, D., 268
Anderson, E. L., 1080
Anderson, L. J., 500, 1686
Andersson, J., 410
Andriamiadana, J., 1382
Angarano, G., 568, 1018
Anstey, N. M., 1994
Antinori, A., 1752
Antonelli, G., 1411
Antonio, M. A. D., 1950
Antony, V. B., 1616
Appice, A., 568
Apple, R. J., 299
Apt, A. S., 150
Araujo, J. M. R., 1153
Archer, J. R., 1214
Archibald, L. K., 87
Arduino, M. J., 391
Argibay, P., 1398
Arias, M., 1521
Armien, B., 876
Armstrong, A., 1424
Arnalich, F., 908
Arnó, A., 56
Arrington, A. S., 884
Arulanandam, B. P., 940
Arvin, A. M., 199
Asahina, Y., 1444
Ashur, Y., 2018
Astemborski, J., 666
Atkins, M., 607
Attenhofer, R., 247
Au, G., 1763
Au, T.-k., 505
Aukrust, P., 195
Aura, J., 426
Auwaerter, P. G., 950
Awaraji, C., 268
Bacci, A., 1957
Bacellar, F., 220
Bacellar, O., 1731, 1735
Bachmann, M., 1957
Bagambisa, G., 1436
Bagarazzi, M. L., 1351
Bagnarelli, P., 285
Bahk, Y. Y., 1307
Bahn, E., 518
Baier, M., 518
Bailly, F., 2003
Baker, J. R., 1939
Balagué, M., 56
Balcewicz-Sablinska, M. K., 1230
Baldanti, F., 1320
Ball, J. K., 27
Ballou, W. R., 1656
Balotta, C., 285
Band, B., 600
Banerjee, S. N., 87, 391
Bapat, A. S., 1072
Bardeguez, A. D., 1536, 1844
Barker, R. H., Jr., 2081
Barlow, D., 600
Barral, A., 1731
Barrett, C., 607
Basco, L. K., 1979
Basgoz, N., 61
Bassett, M. T., 1459
Bataglin, C., 1153
Battistini, L., 858
Bavari, S., 1365, 1370
Bayer, A. S., 1561
Beadle, T. J., 359
Beard, S., 829
Beati, L., 220
Beauvais, L., 1342
Beekes, M., 518
Beeler, J. A., 521
Beeson, J. G., 464
Behets, F. M.-T., 1382
Behr, C., 1753
Behr-Perst, S. I., 141
Bellini, W. J., 950
Bendinelli, M., 838
Bennett, M. K., 1351
Bento, J. L., 1912
Berencsi, K., 843
Berg, G., 1407
Berger, T., 1386
Bergh, A., 1929
Bergström, S., 1929
Berke, T., 514
Berlusconi, A., 285
Bernstein, D. I., 203, 821
Berridge, S., 27
Berrueta, L. R., 206
Best, A. M., 843
Best, J. M., 600
Bethke, F. R., 1682
Bethony, J., 1665
Betti, M., 2074
Beyers, N., 1608
Bhardwaj, N., 359
Biasin, M., 871
Bicart-See, A., 1342
Bienzle, U., 925, 2014
Biggar, R. J., 93, 1784, 1838
Bilello, J., 1064
Bilzer, T., 1695
Bissinger, A. L., 976
Bissuel, F., 2003
Bistoni, F., 1542, 1957
Bjune, G., 242
Blaak, H., 1106
Blake, M. S., 755
Blanchard, S., 1844
Blank, S., 1159
Blasi, E., 1412
Blasi, F., 2074
Blatter, M. M., 2018
Blattner, W. A., 876, 1487
Blé, C., 871
Blumberg, D. A., 397
Blümcke, I., 1695
Boatin, B. A., 1394
Bock, P. J., 1987
Bode, G., 1407
Boeckh, M., 572
Boelaert, J. R., 1412
Boers, P., 1133
Bogerts, B., 1695
Boivin, G., 487
Boken, D., 1700
Boman, J., 2074
Bonhoeffer, S., 865
Böni, J., 1089
Bontempo, F. A., 2027
Boppana, S. B., 702, 970
Borgdorff, M. W., 726, 1238
Borger, P., 1267
Borio, L., 1969
Borkowsky, W., 359
Borregaard, N., 1722
Boshoff, C., 600
Bost, K. L., 1912
Bouhlal, H., 1057
Boulianne, N., 187
Bourboulia, D., 600
Bourezane, Y., 1342
Bourne, E. J., 1757
Bourne, N., 203
Bowonkiratikachorn, P., 50
Boyer, J. D., 1351
Braconier, J. H., 2018
Braitman, D. J., 1282
Brams, P., 268
Brandileone, M. C., 1153
Brandjes, D. P. M., 176
Brännström, T., 1929
Bréchot, C., 15
Breitschwerdt, E., 900
Brennan, J. M., 862
Brenner, H., 1407
Brettle, R. P., 614
Brettler, D. B., 1790
Breukels, M. A., 888
Brewer, T. G., 1282
Bridges, C. B., 1763
Brinker, K., 344
Brisker, J., 1939
Brito Santos, J., 1735
Britt, W., 970
Broadhead, R., 93, 1838
Broersen, S., 1106
Brookes, R., 1656
Broor, S., 959
Brotman, B., 987
Brouwers, P., 626
Brown, A. J. L., 614, 1043
Brown, D. W. G., 600, 829
Brown, E. G., 521
Brown, G. V., 464
Brown, H., 1742

INDEX TO VOLUME 180

Author Index

Abadi, J., 915
Abbott, S., 1361
Abdelhameed, A. A., 1298
Abel, L., 1298
Abernathy, R. A., 1763
Ablashi, D., 1682
Abraham, E., 116
Abrego, P., 1709
Active Bacterial Core Surveillance Team, 1894
Adabayeri, V., 1753
Adachi, J. A., 2053
Adams, D. R., 673
Adams, G. J., 1245
Adams, R. J., 950
Addis, M. F., 1727
Ademowo, O. G., 925
Ades, E., 133
Adimora, A. A., 99
Adler, G., 1407
Adler, S. P., 843
Agnew, D. A., 167
Agosti, J. M., 1064, 2023
Aguero, S. M., 391
Ahmad, M., 862
Aiba, Y., 1374
Akanmori, B. D., 1753
Akatsuka, A., 1374
Akood, M., 1738
Alberici, F., 1018
ALBI (ANRS 070) Study Group, 351
Alcocer, E., 929
Alcorn, T. M., 1018
Alegria, S., 1709
Alessi, M., 2074
Alexander, L., 1790
Allard, R., 1803
Allegra, L., 2074
Almeida, R. P., 1731, 1735
Almera, R., 2081
Alonso, A., 614
Alrajhi, A. A., 1738
Altekruse, S. F., 1214
Alvelo, J. I., 1503
Alves-Oliveira, L. F., 1665
Alvord, W. G., 586
Ambinder, R. F., 824
Amin, A., 1751
Ancuta, P., 1057
Anders, E. M., 2009
Anderson, D., 268
Anderson, E. L., 1080
Anderson, L. J., 500, 1686
Andersson, J., 410
Andriamiadana, J., 1382
Angarano, G., 568, 1018
Anstey, N. M., 1994
Antinori, A., 1752
Antonelli, G., 1411
Antonio, M. A. D., 1950
Antony, V. B., 1616
Appice, A., 568
Apple, R. J., 299
Apt, A. S., 150
Araujo, J. M. R., 1153
Archer, J. R., 1214
Archibald, L. K., 87
Arduino, M. J., 391
Argibay, P., 1398
Arias, M., 1521
Armien, B., 876
Armstrong, A., 1424
Arnalich, F., 908
Arnó, A., 56
Arrington, A. S., 884
Arulanandam, B. P., 940
Arvin, A. M., 199
Asahina, Y., 1444
Ashur, Y., 2018
Astemborski, J., 666
Atkins, M., 607
Attenhofer, R., 247
Au, G., 1763
Au, T.-k., 505
Aukrust, P., 195
Aura, J., 426
Auwaerter, P. G., 950
Awaraji, C., 268
Bacci, A., 1957
Bacellar, F., 220
Bacellar, O., 1731, 1735
Bachmann, M., 1957
Bagambisa, G., 1436
Bagarazzi, M. L., 1351
Bagnarelli, P., 285
Bahk, Y. Y., 1307
Bahn, E., 518
Baier, M., 518
Bailly, F., 2003
Baker, J. R., 1939
Balagué, M., 56
Balcewicz-Sablinska, M. K., 1230
Baldanti, F., 1320
Ball, J. K., 27
Ballou, W. R., 1656
Balotta, C., 285
Band, B., 600
Banerjee, S. N., 87, 391
Bapat, A. S., 1072
Bardeguez, A. D., 1536, 1844
Barker, R. H., Jr., 2081
Barlow, D., 600
Barral, A., 1731
Barrett, C., 607
Basco, L. K., 1979
Basgoz, N., 61
Bassett, M. T., 1459
Bataglin, C., 1153
Battistini, L., 858
Bavari, S., 1365, 1370
Bayer, A. S., 1561
Beadle, T. J., 359
Beard, S., 829
Beati, L., 220
Beauvais, L., 1342
Beekes, M., 518
Beeler, J. A., 521
Beeson, J. G., 464
Behets, F. M.-T., 1382
Behr, C., 1753
Behr-Perst, S. I., 141
Bellini, W. J., 950
Bendinelli, M., 838
Bennett, M. K., 1351
Bento, J. L., 1912
Berencsi, K., 843
Berg, G., 1407
Berger, T., 1386
Bergh, A., 1929
Bergström, S., 1929
Berke, T., 514
Berlusconi, A., 285
Bernstein, D. I., 203, 821
Berridge, S., 27
Berrueta, L. R., 206
Best, A. M., 843
Best, J. M., 600
Bethke, F. R., 1682
Bethony, J., 1665
Betti, M., 2074
Beyers, N., 1608
Bhardwaj, N., 359
Biasin, M., 871
Bicart-See, A., 1342
Bienzle, U., 925, 2014
Biggar, R. J., 93, 1784, 1838
Bilello, J., 1064
Bilzer, T., 1695
Bissinger, A. L., 976
Bissuel, F., 2003
Bistoni, F., 1542, 1957
Bjune, G., 242
Blaak, H., 1106
Blake, M. S., 755
Blanchard, S., 1844
Blank, S., 1159
Blasi, E., 1412
Blasi, F., 2074
Blatter, M. M., 2018
Blattner, W. A., 876, 1487
Blé, C., 871
Blumberg, D. A., 397
Blümcke, I., 1695
Boatin, B. A., 1394
Bock, P. J., 1987
Bode, G., 1407
Boeckh, M., 572
Boelaert, J. R., 1412
Boers, P., 1133
Bogerts, B., 1695
Boivin, G., 487
Boken, D., 1700
Boman, J., 2074
Bonhoeffer, S., 865
Böni, J., 1089
Bontempo, F. A., 2027
Boppana, S. B., 702, 970
Borgdorff, M. W., 726, 1238
Borger, P., 1267
Borio, L., 1969
Borkowsky, W., 359
Borregaard, N., 1722
Boshoff, C., 600
Bost, K. L., 1912
Bouhlal, H., 1057
Boulianne, N., 187
Bourboulia, D., 600
Bourezane, Y., 1342
Bourne, E. J., 1757
Bourne, N., 203
Bowonkiratikachorn, P., 50
Boyer, J. D., 1351
Braconier, J. H., 2018
Braitman, D. J., 1282
Brams, P., 268
Brandileone, M. C., 1153
Brandjes, D. P. M., 176
Brännström, T., 1929
Bréchot, C., 15
Breitschwerdt, E., 900
Brennan, J. M., 862
Brenner, H., 1407
Brettle, R. P., 614
Brettler, D. B., 1790
Breukels, M. A., 888
Brewer, T. G., 1282
Bridges, C. B., 1763
Brinker, K., 344
Brisker, J., 1939
Brito Santos, J., 1735
Britt, W., 970
Broadhead, R., 93, 1838
Broersen, S., 1106
Brookes, R., 1656
Broor, S., 959
Brotman, B., 987
Brouwers, P., 626
Brown, A. J. L., 614, 1043
Brown, D. W. G., 600, 829
Brown, E. G., 521
Brown, G. V., 464
Brown, H., 1742

Brown, N. A., 1757
Browning, P. J., 824
Brueckner, R. P., 1282
Brueggemann, A. B., 404
Brunham, R. C., 234, 774
Bruunsgaard, H., 551
Bucy, R. P., 1851
Buhk, T., 1690
Bulkow, L., 41
Buller, N., 747
Bunnell, J. E., 546
Bunnell, R. E., 1624
Burdick, M., 1220
Burk, R. D., 1424
Burke, R. L., 970, 1459, 1700
Burman, N., 1929
Buster, B. L., 1550
Butel, J. S., 884
Büttner, D. W., 1403
Buxton Bridges, C., 505
Bwayo, J., 234, 1863
Bwayo, J. J., 330
Byrne, G. I., 780
Cadoz, M., 843
Caeiro, J.-P., 2053
Caldwell, H. D., 1252
Caldwell, P., 369
Calfee, D. P., 586
Caliendo, A. M., 862
Callebert, J., 1637
Campbell, G. L., 1436
Campbell, L. A., 238
Campetella, O., 1398
Cann, D., 1686
Cannon, J. S., 824
Cao, Z., 1939
Capobianchi, A., 1747
Cappuccinelli, P., 1727
Capron, A., 454
Carbone, K. M., 521
Carlebach, A., 530
Carlén, B., 737
Carlin, D., 35
Carlo, D. J., 641
Carlone, G. M., 133
Carlos, M. P., 206
Carneiro, M., 1025
Carpenter, C. F., 900
Carr, A., 68, 320
Carreño, V., 262
Carrington, M., 614
Carroll, S. F., 1584
Carson, L. A., 391
Carter, M. J., 514
Carton, C., 1656
Cartter, M. L., 1894
Carvalho, E. M., 1731, 1735
Casadevall, A., 791, 1542
Cass, L. M. R., 586
Cassol, S., 1838
Cassone, A., 448
Castillo, L., 876
Casula, F., 838
Cathomas, G., 247
Cauda, R., 448
Cavaillon, J.-M., 1637
Cavaillon, N. H., 1057
Cavaliere, L. F., 720
Cavaliere, R., 568
Celentano, D. D., 337
Cenci, E., 1957
Centurion-Lara, A., 2060
Cerutti, C., Jr., 2077
Cervin, A., 737
Cesarman, E., 824
Chamat, S., 268
Chamberlin-Brandt, C., 641
Chambers, H. F., 896
Chan, C., 369
Chan, I., 2018
Chancellor, J. A., 1994
Chandraker, A., 755
Chang, C.-S., 2064
Chang, I., 1171
Chang, S.-j., 1569
Chanock, S. J., 1994
Chaovanich, A., 87
Chaowagul, W., 1878
Chapman, S. W., 1259, 1410
Chappell, C. L., 1275
Chapuis, F., 2003
Chattergoon, M. A., 1351
Chau, T. T. H., 1288
Cheang, M., 234
Cheang, M. S., 774
Chearskul, S., 50
Chen, C.-Y., 1382
Chen, D.-S., 191
Chen, P. G.-C., 992
Chen, S.-M., 900
Chen, W., 191
Chen, X. Q., 2018
Chêne, G., 351
Chennebault, J. M., 574
Chensue, S. W., 1987
Chernoff, M., 61
Chiba, S., 834
Chiesa, R., 2074
Childers, T. A., 1503
Childs, J. E., 220
Chimabutra, K., 50
Chiphangwi, J. D., 93
Cho, S.-Y., 1307
Chohan, B. H., 330, 1863
Chokejindachai, W., 1282
Chokephaibulkit, K., 50
Christodoulides, M., 242
Chua, R., 1686
Chung, J.-Y., 1307
Chuong, L. V., 1288
Ciccarelli, R. B., 1351
Ciccorossi, P., 838
Cieslak, P., 1894
Cingolani, A., 1752
Cinti, S., 229
Cipriani, B., 858
Clark, D. R., 1819
Clark, N. C., 1177
Clarke, M., 1763
Classen, C. N., 1608
Clax, P., 1536
Cleary, J. D., 1259, 1410
Clementi, M., 285
Clements, D., 2018
Clements-Mann, M. L., 290
Clerici, M., 871
Clotet, B., 56
Codoceo, R., 908
Coffey, M., 229
Coffman, R. L., 1731
Cohen, A. D., 1351
Cohen, J., 116, 1656
Cohen, M. S., 1382, 2039
Cole, S. P., 1713
Colizzi, V., 858
Colombo, M. C., 285
Colombo, M. M., 1727
Condreay, L. D., 1757
Conn, L., 1763
Connelly, P. W., 473
Cooper, D. A., 68, 320, 607
Corey, G. R., 900
Corey, L., 278, 572
Correa-Oliveira, R., 1665
Corvasce, S., 285
Cosentini, R., 2074
Cosgrove Sweeney, Y. T., 774
Cosma, A., 871
Cotte, L., 351, 2003
Couch, R. B., 1477
Couillin, I., 15
Cova, J. A., 206
Cox, G. M., 534
Cox, J. H., 626
Cox, N. J., 505, 935, 1763
Cox, R. J., 1356
Cox, W. I., 359, 843
Cozzi Lepri, A., 530
Crabb, J. H., 1275, 2056
Crain, M. J., 1577
Crandall, I., 473
Cranston, B., 1487
Crowe, J. E., Jr., 1324
Crowther, L. M., 1757
Cunningham, P. H., 320
Curran, R., 27
Czygan, M., 1695
Dagan, R., 2018
Dahl, H., 2035
Dahlberg, L., 1624
Dallabetta, G., 1382
Dalmau, D., 1597
Dam-Larsen, S., 1819
Daniel, R., 1316
Danila, R., 1894
Danner, S. A., 76, 1050
D'Aquila, R. T., 1043
Darmstadt, G. L., 1718
Das, L., 811
Das, P. K., 811
da Silva, B., 106
Davenny, K., 1514
Davey, R. T., 1334
Davidson, F., 1748
Davis, J. P., 1214
Day, N. P. J., 1288
de Alencar, F. E. C., 2077
de Almeida, G. M. D., 534
De Bernardis, F., 448
de Boer, A. S., 1238
de Boer, M. A., 337
Debord, T., 351
Debre, P., 920
Decazes, J.-M., 351
Decker, M. D., 397
DeFalcon, E., 359
DeFronzo, M. C., 2030
De-Giuli, L., 1320
de Groot, R., 254
de Haas, P. E. W., 726, 1238
de Jesus, A. R., 1731, 1735
De Julio, C., 1320
de la Cámara, R., 571
Delchambre, M., 1656
Delfraissy, J.-F., 920
Dellamonica, P., 843
DeLozier, T., 950
Del Sero, G., 1957
Deng, J.-H., 1466
de Oliveira, C. F., 1153
Derdeyn, C. A., 1851
de Roda Husman, A.-M., 1106
de Ruiter, A., 600
Desai, S. M., 1750
De Serres, G., 187
DeSmet, I., 41
Desrosiers, R. C., 1790
Dessein, A. J., 1298
Dessens, M., 726
Désy, M., 1415
Detmer, J., 1334
Dezzutti, C. S., 1142
Dhawan, V. K., 1561
Diaz, C., 1514
Didier, E. S., 2086
Dieli, F., 225
Dienstag, J. L., 1757
DiFabio, S., 1477
DiGiuseppe, J. A., 824
Dillon, S. B., 35, 708
Dings, M. E. M., 1133
Di Sano, C., 225
District of Columbia Gay Cohort Study, 1784
Division of AIDS Treatment Research Initiative Protocol 007 Study Group, 438
Doern, G. V., 404
Dohn, M., 369
D'Oliveira, A., Jr., 1735
Dolmans, W. M. V., 176
Donis, J. H., 206
Donnelly, G. A. E., 1590
Donskey, C. J., 384
Dore, G. J., 607
Dorn, J., 1033

Dörries, K., 1690
Dorrucci, M., 1018
d'Ostiani, C. F., 1957
Dow, J. L., 1503
Doyle, M. L., 35
Doyle, W. J., 10
Drew, W. L., 847
Driss, F., 15
Dromer, F., 1637
Drummond, A. H., 1142
Drusano, G., 438, 1064
Dubeaux, B., 1342
Duerr, A., 337
Duliege, A.-M., 290, 970, 1700
Dumler, J. S., 546, 900
Dumon, B., 1342
Dumoulin, F. L., 1704
Dunn, J. A., 2039
Dunzendorfer, S., 216
DuPont, H. L., 1275, 2053
Dupré, L., 454
Durlacher, R. R., 2077
Durrant, S., 912
Duval, B., 187
Dworkin, M. S., 621
Dykes, J. K., 133
Dzinjalamala, F., 464
Eampokalap, B., 87
Easterbrook, P. J., 1096
Edelman, R., 2056
Edmonds, K., 2069
Edwards, K. M., 397, 1569
Eggers, C., 1690
Einsele, H., 1748
Elagib, K. E., 1298
Eliopoulos, G. M., 1177
Elkins, W. R., 950
Ellenberger, D. L., 673, 1033
Elliott, M., 254
Ellis, B. A., 220
Ellner, J. J., 2069
El-Madhun, A. S., 1356
Elwali, N.-E. M. A., 1298
Emery, V. C., 695, 702
Endoh, M., 1374
Engels, E. A., 1784
Enger, C., 299
Englund, J. A., 397
Ennis, F. A., 1429, 2030
Enomoto, N., 1001, 1444
Erdman, D. D., 500, 1686
Eriksson, B. K. G., 410
Eron, J. J., Jr., 2039
Esposito, G., 2074
Essex, M. E., 1116
Estrada-Garcia, M. T., 2053
Evans, T. G., 290, 2023
Excler, J.-L., 290
Facchi, G., 285
Fahey, J. L., 61
Falkai, P., 1695
Falkovitz Halpern, M. S., 199
Falusi, A. G., 925
Fang, Z.-Y., 1122
Farrar, J., 1361
Farshy, C., 1624
Farzadegan, H., 1025
Fasano, A., 1709
Fast, P., 290, 1080
Feinberg, J. E., 695
Fenyves, D., 1597
Ferchal, F., 351
Fernández, M., 262
Fernández-Rañada, J. M., 571
Fernandez-Sesma, A., 579
Fialaire, P., 574
Fidel, P. L., Jr., 802
Filho, Á. C., 1731
Filho, D. C., 1731
Finegold, M. J., 884
Finzi, D., 1827
Fiori, P. L., 1727
Fischer, J. E., 714
Fischer, P., 1403
Fiscus, S. A., 99, 2039
Fisher, R. G., 708, 1324
Fiske, W. D., 862
Fitting, C., 1637
Fjaertoft, G., 2035
Flanagan, K. L., 1656
Flanigan, T. P., 862
Fleckman, P., 1718
Fleming, D. M., 254
Flerlage, A. N., 685
Fleuridor, R., 1526
Fleury, H., 1342
Flore, O., 1466
Flynn, P. M., 1844
Folks, T. M., 1033
Fong, I. W., 106
Foongladda, S., 50
Forleo-Neto, E., 1153
Fornai, C., 838
Forsgren, A., 737
Forthal, D. N., 1338, 1406
Foudraine, N. A., 76, 1050
Fox, L., 61
Francis, D. P., 1080
Franco, E. L., 1415
Frasch, C. E., 747
Fraschetti, M., 1747
Fredricks, D. N., 1386
Freedman, D., 2056
Frendéus, B., 1220
Frey, S. E., 1700, 2018
Fridland, A., 1844
Fridlund, C. A., 673
Friscia, G., 225
Fritz, R. S., 586
Froland, S. S., 195
Frothingham, R., 1245
Fujihashi, K., 122, 1477
Fujimoto, J., [illegible]02
Fukada, M., [illegible]8
Fukuda, K., [illegible], 1763
Fukuda, Y., [illegible]3
Fulhorst, C. F., 966
Furukawa, H., 834
Galli, M., 285
Galván, E. M., 419
Gam, A., 564
Gan, H. X., 1230
Gandhi, T. K., 900
Gandia, J., 1536
Ganem, D., 1010
Gao, S.-J., 1466
Garcia, L. F., 1521
García Rivello, H., 1398
Gaur, L. K., 234
Gauthier, J., 1757
Gazzard, B. G., 1096
Gazzinelli, G., 1665
Gebhard, D. H., 1503
Geertsma, M. F., 649
Geginat, G., 1186
Gelas, P., 2003
Gentile, D. A., 10
Gentile, G., 1747
Gerber, J. G., 1833
Gerberding, J. L., 896, 1809
Geretti, A.-M., 1133
Gerna, G., 1320
Gershman, K., 1624
Ghildyal, R., 2009
Ghosh, K., 1674
Gie, R. P., 1608
Giermakowska, W. K., 641
Gilbert, M. J., 1064
Gilles, A. A., 1394
Gioulekas, E., 904
Giraldo, P., 912
Girard, P.-M., 1057
Gismondi, A., 156
Giusti, R. M., 876
Glass, G. G., 220
Goade, D., 2030
Godaly, G., 1220
Godleski, M., 594
Goedert, J. J., 299, 1010, 1682
Goh, L.-E., 607
Goka, B. Q., 1753
Gold, H. S., 1177
Goldblatt, D., 538
Gonczol, E., 843
Gonser, T., 1407
Goodgame, R., 929
Gooley, T., 572
Gopal, R., 600
Gordeuk, V. R., 1452
Gore, S. M., 614
Gormley, J. M., 862
Gorse, G. J., 290, 1080
Gottfredsson, M., 534
Goudsmit, J., 1050
Gougeon, M. L., 858
Grabowska, A. M., 27
Gracia, F., 876
Graf, M. D., 685
Graham, B. S., 290, 708, 714, 1324
Granger, D. L., 1994
Graviss, E. A., 1245
Gray, B., 1569
Gray, R. H., 1316
Grayston, J. T., 238
Grazia Revello, M., 1320
Green, S., 1429
Greenberg, D., 2018
Greenough, T. C., 1790
Greer, C. E., 1424
Grey, P., 320
Griego, S. D., 35
Griffin, D. E., 950
Griffiths, P. D., 695, 702
Groeneveld, P. H. P., 649
Gruters, R., 1133
Grywacz, M., 695
Guenthner, P. C., 1142
Guerra, M., 1803
Guerrant, R. L., 167
Guèye-Ndiaye, A., 1116
Guiney, D. G., 1713
Günthard, H. F., 1043
Günther, M., 2014
Gutierrez, K. M., 199
Gutmann, L., 555
Guy, R. A., 473
Gwanzura, L., 1459
Gyulai, Z., 843
Haaheim, L. R., 1356
Haderer, P., 1424
Hadley, W. K., 1809
Hafner, R., 438
Haga, H.-J., 1
Hahn, B.-I., 1072
Hall, J. E., 2039
Hallaby, T., 854
Hallensleben, W., 1695
Hamann, D., 1050
Hamouda, T., 1939
Hamprecht, K., 491
Hampson, A. W., 935
Hanchard, B., 1487
Handgretinger, R., 491
Hang, L., 1220
Hanrahan, J. A., 384
Hansen, J.-E. S., 1819
Hanson, D. L., 621
Haraoka, M., 1220
Harrigan, P. R., 1347
Harrison, C., 1700
Harrison, L. H., 41, 1894
Hartley, C., 2009
Harzic, M., 1342
Hasan, M. S., 2023
Haubrich, R., 1338
Hawes, S. E., 1950
[illegible]yakawa, T., 1328
[illegible]vden, F. G., 586
[illegible]es, M. M., 1939
[illegible]ward, G. S., 824
[illegible]mi, M., 1738
[illegible]ald, A. E., 534
Hebart, H., 1748
Heckels, J. E., 242
Heeney, J. L., 1494

Hegarty, B., 900
Hellmann, N., 865
Helminen, M., 496
Hemphill, M. L., 935
Hendershot, J. D., 2030
Henry, D., 254
Heppner, D. G., Jr., 1282
Hernández, M. R., 206
Herold, M., 1452
Herpin, B., 1334
Herrero, M., 262
Herulf, M., 542
Hervé, M., 454
Hien, T. T., 1288
Higgins, A. W., 1394
Hill, A., 530
Hill, A. V. S., 1656
Hill, B. C., 391
Hillier, S. L., 426, 1863, 1950
Hilsenbeck, S. G., 509
Hirabayashi, S., 1700
Hirsch, C. S., 2069
Hirsch, M., 659
Hirschel, B., 659, 850, 1803
Hjelle, B., 2030
Ho, D. D., 865
Ho, M., 1288
Ho, Y.-y., 505, 755, 762, 1763
Hobbs, M. R., 1994
Hockett, R. D., 1851
Hoen, B., 1342
Hoerneman, B., 780
Hof, H., 1186
Hofer, M., 1695
Hoffmann, M. K., 1072
Hogg, R. S., 1347
Holland/Flevoland Kawasaki Disease Study Group, 1869
Holm, S. E., 410
Holmgren, D., 720
Holzhüter, B., 491
Honecker, U., 1704
Hoofnagle, J. H., 1334
Hooton, T. M., 61
Hoover, D. R., 93
Hoover, R. N., 1424
Horie, H., 1902
Horisberger, M. A., 262
Horowitz, H. W., 1072
Horton, J., 1282
Hotez, P. J., 1674
Houghton, J.M., 211
Hsia, K., 344
Hsieh, R.-H., 1080
Hsu, C.-W., 992
Huang, C.-H., 191
Huang, S., 1536
Hubert, J.-B., 920
Hudson, M. C., 1912
Huebner, R. E., 1171
Huerre, M., 1637
Hufert, F. T., 1695
Hughes, J. P., 278
Hughes, S., 1252
Huh, S., 1307
Hulskotte, E. G. J., 1133
Hung, K.-Y., 191
Hu-Primmer, J., 1763
Hurlburt, D., 41
Hurme, M., 496
Husman, A.-M. R., 854
Hutchings, M., 1819
Hutton, R. A., 384
Hviid, L., 1753
Ibarra, J., 2018
Igarashi, C., 834
Ikeda, H., 2048
Inagi, R., 50
Inderlied, C. B., 438
Indorf, A. S., 1603
Indorf, C., 41
Indridason, Ó. S., 534
Insel, R. A., 577
Ioannidis, J. P. A., 2044
Ireland, J., 203
Irving, W. L., 27
Ishikawa, N., 2048
Ishitoya, S., 1378
Itoh, K., 880, 1750
Ivanoff, B., 2089
Ivanyi, J., 225
Ives, N., 1096
Izu, A. E., 1700
Izumi, N., 1001
Izurieta, H. S., 505
Jackson, D. J., 330
Jackson, E., 673
Jackson, J. B., 61
Jackson, S., 1080
Jacobson, J. M., 61
Jacobson, R. M., 2018
Jacobson, S., 685
Jahn, G., 491, 976
Jameson, C. L., 27
Janes, M., 1838
Janoir, C., 555
Jansen, W. T. M., 888
Janson, H., 737
Jaramillo, A. B., 320
Jarosinski, P., 626
Jarvis, W. R., 87, 391
Javadian, M. A., 1351
Jenkins, J. K., 1410
Jensen, F. C., 641
Jenson, H. B., 509, 1466
Jeremias, J., 912
Jessen, H., 1827
Jiang, X., 514
Jiang, Z.-D., 2053
Jimenez, E., 1844
Jiménez, M., 908
Jin, L., 829
Johansen, J. S., 1722
Johnson, D. R., 1921
Johnson, J. E., 708
Johnson, J. L., 2069
Johnson, K., 1939
Johnson, K. D., 892
Johnson, S., 35
Johnson, S. E., 133
Johnson, T. R., 714, 1324
Johnson, V. A., 99, 1043
Jones, D., 220
Jones, G. R., 242
Jones, J. L., 621
Jones, L. P., 500
Jou, A., 56
Journot, V., 351
Juan, M., 56
Junker, D., 1186
Junker, P., 1722
Kain, K. C., 473
Kalayanarooj, S., 1429
Kalayoglu, M. V., 780
Kalish, L. A., 1514
Kamada, M., 834
Kamizono, S., 880
Kang, S.-Y., 1307
Kanki, P. J., 1116
Kao, J.-H., 191
Kaplan, E. L., 1921
Kaplan, J. E., 876, 1338
Kaplan, R. F., 377
Karatzas, N., 904
Kariwa, H., 2030
Karron, R. A., 41
Kartalija, M., 896
Kashuba, A. D. M., 2039
Kaslow, R. A., 299, 847
Kasper, D. L., 892
Kastenbauer, S., 1164
Katano, Y., 1328
Kato, Y., 2048
Katz, J. M., 505, 1763
Katzenstein, D., 1459
Kauffman, H. F., 1267
Kauffmann, R. H., 1050
Kaufmann, G. R., 320
Kaufmann, S. H. E., 141
Kawabata, S., 1477
Kawamata, J., 1436
Kawanishi, T., 685
Kawichai, S., 337
Kazanjian, P., 229
Kazatchkine, M. D., 1057
Kedes, D., 1010
Keefer, M. C., 290, 1080
Keenan, B., 1338
Keene, O. N., 254
Keet, I. P. M., 299
Keitel, W. A., 397
Kelleher, A. D., 320
Kenney, R., 564
Kenny, J., 99
Kerkhof-Garde, S., 76
Kester, K. E., 1656
Kharitonov, V. F., 1713
Kilby, J. M., 1851
Kim, K. H., 211
Kimani, J., 234
Kimura, A., 1171
Kind, C., 1089
King, C. H., 1142
Kirchhoff, F., 1494, 1790
Kirnbauer, R., 1424
Kitzis, M.-D., 555
Kiwanuka, N., 1436
Kiyokawa, N., 1902
Kiyono, H., 122, 1477
Klein, M. R., 76, 299
Klein, T., 254
Klimov, A. I., 935
Klingebiel, T., 491
Klingman, K. L., 404
Klugman, K. P., 1171
Knayer, U., 1407
Knight, S., 695
Ko, A. I., 1735
Kodama, S., 122
Koedel, U., 1164
Koehler, J. E., 1386
Koenig, S., 35
Koëter, G. H., 1267
Koga, Y., 1374
Koide, N., 2048
Kojima, H., 834
Kokori, S. I., 2044
Kolberg, J., 1334
Kole, L., 811
Kollaritsch, H., 2018
Kolman, C. J., 2060
Kong, L. K., 900
Kong, Y., 1307
Koo, F. C., 509
Kopf, M., 1957
Korah, R. M., 211
Kordossis, T., 2044
Kositanont, U., 50
Koster, F. T., 2030
Koutsoukos, M., 1656
Kovacs, J. A., 1969
Kramer, R. E., 1259
Krasinski, K., 359
Kreiss, J. K., 330, 1863
Kremer, K., 726
Kretschmar, M., 1186
Krieger, J. N., 278
Krohn, M. A., 426
Kroon, F. P., 649
Kruger, H., 876
Kruse, D., 41
Ksiazek, T. G., 220, 966
Kuehnert, M. J., 391
Kuijpers, T. W., 1869
Kukkula, M., 1771
Kuli-Zade, I., 1122
Kullberg, B. J., 1408, 1648
Kumagai, M., 626
Kumagai, T., 834
Kumwenda, N., 93, 1838
Kunz, L. F., Jr., 1153
Kuo, C.-c., 238
Kuo, C.-H., 2064
Kuppens, L., 2089
Kuppermann, B. D., 1338
Kurane, I., 1429

Kurata, T., 50
Kurimoto, M., 1878
Kuritzkes, D. R., 570, 1043
Kurono, Y., 122
Kurosaki, M., 1001, 1444
Kurtzhals, J. A. L., 1753
Kuter, B., 2018
Kwong, H., 505, 1763
Kyle, D. E., 1282
Kyriaki, D., 2044
Labbet, W., 600
Lagergren, Å., 542
Lagos, R., 1709
Lahdenpohja, N., 496
Lal, A. A., 559
Lal, R. B., 559, 1033, 1142
Lalvani, A., 1656
Lam, P. K., 1809
Lambert, J., 1803
Lambert, J. S., 1080
Lamunu, M., 1436
Landesman, S. H., 1514
Landucci, G., 1338
Lane, C., 56
Lange, J. M. A., 76, 659, 854
Lanier, E. R., 310
Larsson, M., 359
Lascoux, C., 1342
Laserson, K. F., 2081
Lathey, J. L., 344
Latif, A. S., 1459
Lau, D. T.-Y., 1334
Lauw, F. N., 1878
Lavebratt, C., 150
LaVerda, D., 780
Lavreys, L., 330, 1863
Layrargues, G. P., 1597
Lazar, J. G., 847
Leach, C. T., 509
Leary, T. P., 1750
Leavitt, R., 659
LeBlanc, R. A., 594
LeBlanc, S., 299
Le Chenadec, J., 920
LeClaire, R. D., 1365
Lednicky, J. A., 884
Lee, B. L., 896
Lee, D.-H., 987
Lee, E., 1656
Lee, J. Y., 847
Lee, M., 505, 1763
Lee, S.-H., 191
Leen, C. L. S., 614
Lefebvre, E.-A., 369
Lefkowitz, L., 1894
Lefrère, J.-J., 526
Leguizamón, M. S., 1398
Lehky, T. J., 685
Leifeld, L., 1704
Leisenring, W., 572
Leist, T. P., 685
Lemke, J. H., 1584
Lendvai, N., 791
Leombruno, D., 41
Letendre, S. L., 310
Levesque, M. C., 1994
Levin, A., 876
Levin, M. C., 685
Levine, M. M., 1709, 2089
Levine, P. H., 876
Lew, J. F., 1514
Ley, C., 1459
Li, C., 1316
Li, L.-F., 1851
Liaw, Y.-F., 992
Lichtenwalner, A. B., 774
Lie, Y. S., 865
Lieb, K., 1695
Lieberman, J., 1827
Lien, E., 195
Lim, W., 99, 1763
Lima, A. A. M., 167
Lindberg, S., 737
Linde, A., 2035
Linden, J., 1550
Linnig, S., 2014
Lira, R., 564
Lisziewicz, J., 1827
Liveris, D., 720
Livingston, E., 1536
Livio, S., 2056
Ljung, T., 542
Loc, P. P., 1288
Lo Caputo, S., 871
Lockett, S. F., 614
Logan, K., 2086
Logigian, E. L., 377
Logue, C., 1748
Loison, J., 574
Looareesuwan, S., 1282
Loomis-Price, L. D., 626
Lopalco, L., 871
López, J., 908
Lori, F., 1827
Lorincz, A., 1316
Lortholary, O., 1637
Losonsky, G. A., 1709, 2056
LoVerde, P. T., 1665
Lovevsky, M., 1452
Lu, J., 1590
Lu, X., 1763
Ludlam, C. A., 1748
Lukehart, S. A., 2060
Lundberg, J. O. N., 542
Lunel, F., 574
Lutwama, J. J., 1436
Lutz, M. W., 1757
Luzuriaga, K., 1790
Luzza, F., 1407
Lyles, C. M., 666, 1025, 1018
Lyles, R. H., 1526
Ma, L., 1969
MacDonald, K. S., 1686, 1886
Mach, M., 1748
Machado, P., 1735
Machekano, R., 1459
Mackinnon, F. G., 755
Maclean, I., 1886
MacPhail, L. A., 61
Macrae, D. R., 1010
Madelaine, I., 351
Madero, R., 908
Maggi, F., 838, 1411
Magierowska, M., 920
Magnusdottir, A. B., 737
Maguire, G. F., 473
Maguire, J. H., 2081
Magzoub, M. M. A., 1298
Mai, N. T. H., 1288
Maitra, A., 959
Mak, K. H., 505, 1763
Makela, M., 254
Makharia, A., 564
Maldonado, Y., 199
Maloney, E. M., 876, 1487
Malonza, I. M., 1886
Maluf, E. M. C. P., 1153
Man, C. Y., 254
Mancini, M., 15
Mancino, G., 858
Mandaliya, K., 330, 1863
Mann, D., 299
Mann, R. B., 824
Manns, A., 1487
Manos, M. M., 1424
Marcantel, B., 929
Marchal, F., 850
Marchi, S., 838
Marfil, S., 56
Margolick, J. B., 337, 666
Marina, R., 369
Mariotti, M., 526
Markham, R. B., 1025
Markowitz, M., 865
Marquet, S., 1521
Marriott, I., 1912
Marston, E., 220
Martin, H. L., 1863
Martin, J., 262
Martin, J. N., 896, 1809
Martin, M. P., 614
Martin, P., 1929
Martínez, M. A., 56
Martínez-Picado, J., 56
Martini, F., 858
Martino, P., 1747
Marumo, F., 1001, 1444
Masliah, E., 1695
Masur, H., 1969
Mathewson, J. J., 2053
Mathiesen, L., 1819
Matson, D. O., 514
Matsumoto, H., 880
Matsuoka, M., 880
Maunula, L., 1771
May, J., 925
Mayaux, M.-J., 920
Mazur, M. H., 2018
Mazzoli, S., 871
Mazzotta, F., 871
Mazzucchelli, R., 285
Mazzulli, T., 1686
Mbawuike, I. N., 1477
Mbelle, N., 1171
Mboup, S., 1116
McCutchan, J. A., 310
McDonald, L. C., 87
McElrath, M. J., 278, 290, 1080, 1406
McFarland, W., 1459
McGeer, A., 1686
McGhee, J. R., 122, 1477
McIntosh, K., 1514
McIvor, R. A., 369
McKay, D. M., 1590
McKenna, D., 720
McKinney, R., 99, 1536
McMichael, A. J., 359
McMullen, D. J., 847
McNamara, J., 1080
McShan, W. M., 1921
Meacci, F., 871
Meanger, J., 2009
Meehan, M. P., 1316
Meenhorst, P. L., 1050
Meer, J. W. M., 1408
Meibohm, A., 659
Meierhofer, C., 216
Meis, J. F. G. M., 1648
Melbourne, K., 1064
Melissano, G., 2074
Mellors, J., 659
Mencacci, A., 1957
Mergani, A., 1298
Meric, C., 843
Meshnick, S. R., 1987
Messer, R., 1252
Metcalf, J. A., 1334
Metzger, D. W., 940
Meyer, C. G., 925
Meyer, L., 920
Meyer, W. A., III, 344
Mhango, C., 464
Michel, M. L., 15
Michon, F., 755
Miedema, F., 76, 299, 1050, 1819
Mikolich, D., 1064
Miley, W. J., 1487
Milhous, W. K., 1282
Millard, E., 538
Miller, E., 538
Miller, K. D., 1334
Miller, V., 530
Mills, J., 2009
Mimica, I. M., 1153
Mimica, L. M. J., 1153
Miner, R., 847
Mink, C. M., 397
Miotti, P. G., 93, 1838
Miralles, G. D., 1851
Mirowski, G., 1386

Misrahi, M., 920
Misukonis, M. A., 1994
Mitchell, D. K., 514
Mitsumori, K., 1378
Mittler, R. S., 1072
Moazed, T. C., 238
Mobashery, N., 1735
Mocetti, E., 1398
Mochizuki, M., 880
Mockenhaupt, F. P., 925
Moellering, R. C., Jr., 1177
Moens, U., 1
Mogi, G., 122
Mohamed-Ali, Q., 1298
Mohammed, K. A., 1616
Mohle-Boetani, J. C., 1361
Molden, J., 1010
Molina, J.-M., 351
Molyneux, M. E., 464, 1742
Monari, C., 1542
Monferran, C. G., 419
Mongillo, A., 1064
Monno, L., 568
Monroe, S. S., 514
Montagnoli, C., 1957
Montaner, J., 369, 1347
Montefiori, D., 290
Montiel, C., 908
Monto, A. S., 254
Moore, B. S., 987
Moore, S. R., 167
Moormann, A. M., 1987
Moran, T. M., 579
Morand-Joubert, L., 526
Morcos, E., 542
Morelli, N., 2074
Morey, G., 369
Morgan, O. S. C., 1487
Moris, P., 1656
Moroni, M., 285
Morrica, A., 838
Morrison, R. P., 780, 1252
Morrison, S. G., 780
Morse, S. A., 1382
Mosci, P., 1957
Moses, S., 1886
Moss, R. B., 626, 641
Mounts, A. W., 505
Mousavi-Jazi, M., 2035
Mtimavalye, L., 93
Mtimivalye, L., 1838
Muenz, L. R., 397
Muerhoff, A. S., 1750
Mugerwa, R., 2069
Müller, F., 195
Mulligan, M. J., 290
Multicenter Hemophilia Cohort Study, 1784
Münch, J., 1494
Munk, M. E., 141
Muñoz, J. F., 206
Murphy, B. R., 950
Murphy, E. L., 1777
Murphy, T. F., 404
Murray, P. G., 824
Musey, L. K., 278
Mushahwar, I. K., 1750
Musil, R., 641
Musser, J. M., 1245, 1751
Muth, K., 438
Mwenechanya, J., 1742
Myerson, D., 572
Nadal, D., 1089
Nadelman, R. B., 720
Nagachinta, T., 337
Nagelkerke, N. J. D., 1238
Nahm, M. H., 1569
Najjemba, R., 1436
Nakano, I., 1328
Nasreen, N., 1616
Nass, C. C., 1777
Nataro, J. P., 167
National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group, 61
National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group, 290
Naus, M., 187
Ndinya-Achola, J. O., 330, 1863, 1886
Neal, K. R., 27
Nelson, K. E., 337
Nemo, G., 1777
Netea, M. G., 1408, 1648
Neuhaus, R., 2014
Newhall, W. J., 1624
Newman, G. W., 1142
Newman, R. D., 167
Neylans, L. L., 1159
Nibbering, P. H., 649
Nicholas, J., 824
Nicholson, N. C., 1912
Nichterlein, T., 1186
Nicolini, U., 1320
Nielsen, J. O., 1819
Nielsen, S. D., 1819
Nikonenko, B. V., 150
Nilsson, I.-M., 1370
Nimmannitya, S., 1429
Nisalak, A., 1429
Nishizaka, S., 880
Nishizawa, T., 1750
Nixon, D. F., 359
Niyomthai, S., 337
Nkrumah, F. K., 1753
Nøkleby, H., 242
Nordal, K. P., 195
Nordenbaek, C., 1722
Nordøy, I., 195
Norgren, M., 410
Norley, S. G., 1133
Norrby, S. R., 2018
Norsted, T., 2035
Notermans, D. W., 76, 1050
Nowakowski, J., 720
Nyange, P. M., 1863
Nyirenda, T., 1987
O'Brien, S. J., 1790
O'Brien, T. R., 1010, 1682
O'Brien Gress, J., 2018
O'Callaghan, C., 359
Ochi, J., 268
Oettle, H., 976
Offner, F., 1452
Ogg, G. S., 359
Ogura, Y., 1444
Okamoto, H., 1750
Okhuysen, P. C., 1275
Okui, T., 834
Okwera, A., 2069
Olumese, P. E., 925
Omar, S., 1886
Opal, S. M., 1584
Opravil, M., 850
Orenstein, J. M., 824
Orle, K., 1886
Orlikowsky, T., 1072
Ortona, L., 1752
Osei, A., 1
O'Shaughnessy, M. V., 1347
Osta, M., 268
Osterhaus, A. D. M. E., 1133
Ostrowsky, B. E., 1177
O'Sullivan, C. E., 847
O'Sullivan, M. J., 1536
Othieno, C., 2069
Othoro, C., 1754
O'Toole, M., 940
Ottaway, C. A., 106
Otten, R. A., 673
Ottenkamp, J., 1869
Otto, M., 518
Ouadrhiri, Y., 1195
Ownby, H., 1777
Owsley, D. W., 2060
Pais, L. B., 133
Pakker, N. G., 1050
Palardy, J. E., 1584
Palefsky, J., 1682
Pallone, F., 1407
Pan, L.-Z., 268
Pang, L. W., 2077
Paoletti, L. C., 892
Papachristou, F., 904
Papagno, L., 285
Pappagianis, D., 243
Pardo, M., 262
Parejo, N. A., 1584
Paris, S. C., 1521
Park, H., 579
Parker, R. A., 708
Parkin, N. T., 865
Parkinson, A., 41, 1577
Parsonnet, J., 1459
Pasha, S. T., 959
Pasi, O. G., 896
Pass, R. F., 702, 970, 1700
Passador, S., 1390
Pastori, C., 871
Patel, A., 10
Pathan, A. A., 1656
Patil, S., 1536
Patton, D. L., 774
Payan, C., 574
Pearlman, E., 1394
Pedersen, B. K., 551
Peebles, R. S., 714
Peeling, R. W., 234, 774
Pellegrin, I., 351
Peng, A. W., 586
Percell, S., 970, 1700
Perdreau-Remington, F., 896, 1809
Pereira, A. S., 2039
Peret, T. C. T., 1686
Perez-Oronoz, G., 935
Perfect, J. R., 534
Perkins, B. A., 1894
Perkins, D. J., 1994
Perriens, J., 1886
Perrin, L., 850
Persat, F., 2003
Pesnicak, L., 594
Peters, B. S., 600
Peters, C. J., 966
Peters, P., 2069
Petersen, K. M., 41
Peterson, D. M., 438
Petralanda, I., 2081
Petropoulos, C. J., 865
Pezzotti, P., 1018
Pfarr, D. S., 35
Pfister, H. W., 1164
Phillips, A. N., 530
Phu, N. H., 1288
Pica, F., 1747
Piccoli, M., 156
Pichard, E., 574
Pichichero, M. E., 1390
Pichyangkul, S., 1429
Pickering, L. K., 514
Pieniazek, D., 673
Piens, M.-A., 2003
Pietrella, D., 1542
Pilon, R., 1838
Pincus, S., 843
Pinedo, S., 1869
Pinel, J., 892
Pinto de Andrade, A. M., 1727
Pirofski, L.-a., 915, 1526
Pistello, M., 838
Pitt, J., 1514
Pizzo, P. A., 626
Plebanski, M., 1656
Plotkin, S. A., 843
Plummer, F., 234
Plummer, F. A., 1886
Poate, T., 1603
Poccia, F., 858

Podglajen, I., 555
Pöhlmann, S., 1494
Pol, S., 15
Poland, G. A., 2018
Pole, A., 1994
Pollack, H., 359
Pollak, S., 1695
Pontesilli, O., 76
Poon, S.-K., 2064
Popovic, T., 1894
Popper, S. J., 1116
Portegies, P., 854
Poser, S., 518
Poyart, C., 555
Prado, J. M., 1415
Prado, V., 1709
Prescott, L. E., 1748
Pribble, J. P., 1584
Price, P. A., 1722
Prince, A. M., 987
Prince, G. A., 35
Prins, J. M., 1878
Prix, L., 491
Proctor, M. E., 1214
Profy, A. T., 203
Protocol 039 Study Group, 659
Pujol-Borrell, R., 56
Pustai, A. K., 1153
Quakyi, E. K., 747
Quinn, F. D., 1142
Quinn, T. C., 93, 666
Quirk, S. B., 391
Quiroga, J. A., 262
Qvist, J., 551
Rabe, L., 426
Rabenau, H., 530
Rabkin, C. S., 1466
Rabodonirina, M., 2003
Raboud, J. M., 1347
Radke, C., 976
Rae, S., 1347
Raffi, F., 1342
Ragnaud, J.-M., 1342
Ragni, M. V., 2027
Rahim, I., 1738
Rahoud, S., 1298
Rai, A., 959
Rakwar, J. P., 330
Ramaswamy, S., 1245, 1751
Ramegowda, B., 1205
Ramp, W. K., 1912
Rana, K., 1064
Rancinan, C., 351
Randriamanga, R., 1382
Randrianasolo, D., 1382
Ransom, R., 1624
Rappelli, P., 1727
Rasamilalao, D., 1382
Ratterree, M., 802
Ratto-Kim, S., 626
Rawlins, S., 659
Rayanade, R. J., 1072
Rayfield, M. A., 673
Rayhane, N., 1637
Raynal, C., 2003
Read, J. S., 1514
Reeve, P., 521
Regnery, H. L., 935
Regnery, R. L., 220
Reinap, B., 892
Reingold, A. L., 1894
Reinke, P., 2014
Reisinger, K., 2018
Rekvig, O. P., 1
Reller, L. B., 87
Relman, D. A., 1386
Remold, H. G., 1230
Ren, L., 987
Reporter, R., 1361
Repping, S., 1819
Resistant Host Perspective Study Group, 285
Reusser, P., 247
Reynolds, K. K., 2023
Rezza, G., 1018
Rheanpumikankit, S., 87
Ribeiro-Filho, A., 912
Rice, L. B., 384
Rice, P. A., 762
Rich, K. C., 1514
Richardson, B. A., 1863
Richardson, M., 1608
Richey, C. M., 1632
Richieri, S. P., 641
Richman, D. D., 1043
Richmond, P., 538
Ridolfo, A. L., 285
Riederer, P., 1695
Riente, L., 838
Rijkers, G. T., 888
Ringwald, P., 1979
Risberg, K., 649
Rita, F. M., 1727
Riva, E., 1411
Riveau, G., 454
Rivers, C., 299
Rizvi, A., 133
Robb, M. L., 626
Robbins, B., 1844
Roberts, M. C., 1577
Robertson, J. R., 614
Robertson, S., 2069
Robinson, S. M., 685
Robison, V., 337
Rocha, P. N., 1731
Rochette, L., 187
Rochford, R. A., 1987
Rodman, J. H., 1844
Rodríguez, J., 1521
Rodriguez, J. F., 1844
Rogers, P. D., 1259, 1410
Rogerson, S. J., 464, 1742
Rohan, T. E., 1415
Roilides, E., 904
Rolfs, R., 1624
Rollag, H., 195
Romani, L., 1957
Romero-Steiner, S., 133
Romeu, J., 56
Ronald, A. R., 1886
Rood, M., 220
Roos, M. T. L., 76, 1050, 1869
Rose, D. A., 1809
Rosenberg, E., 1827
Rosenberg, P. S., 1010, 1784
Rosenfeld, M. E., 238
Rosenqvist, H., 1
Rosenstein, N. E., 1894
Ross, M. W., 1245
Ross, R. A., 892
Rostron, T., 1096
Rota, P. A., 950
Roth, G. A., 419
Rothenbacher, D., 1407
Rothman, A. L., 1429
Rottmann, C., 530
Roudot-Thoraval, F., 526
Rousseau, M.-C., 1415
Roux, A., 1057
Rouzioux, C., 920
Rowe, M., 2018
Rowe, T., 1763
Rowland-Jones, S. L., 1096
RSV Alaska Study Group, 41
Rubens, C. E., 1718
Rubin, L., 133
Rubin, S. A., 521
Rubin, S. R., 1159
Rudolph, K. M., 1577
Ruiz, L., 56
Runer, T., 737
Rungruengthanakit, K., 337
Rupar, D., 99
Rutschmann, O. T., 850
Rwaguma, E. B., 1436
Ryder, S. D., 27
Saag, M. S., 847, 1851
Sabin, C., 530, 695
Sabin, C. A., 600
Sacks, D., 564
Saeed, O. K., 1298
Safaeian, M., 1025
Saito, A., 834
Sakuma, I., 1001
Salerno, A., 225
Salmen, S., 206
Salmi, D., 1921
Salvi, A., 871
Samore, M. H., 1177
Sampson, S. L., 1608
Samuel, J. E., 1205
Sánchez, F. O., 1521
Sandelli, S. L., 626
Sanders, E. J., 1436
Sanders, L. A. M., 888
San Martin, O., 1709
Santambrogio, S., 285
Santoni, G., 156
Santosham, M., 41
Saraiva, E., 564
Sarasini, A., 1320
Sarr, A. D., 1116
Sasso, D. R., 1142
Sato, C., 1001, 1444
Sauder, C., 1695
Sauerbruch, T., 1704
Savary, J., 641
Sawtell, N. M., 821
Sayegh, M. H., 755
Scannon, P. J., 1584
Scarabaggio, T., 568
Scerpella, E., 659
Schaberg, T., 141
Schable, C., 1033
Schacht, A.-M., 454
Schacker, T. W., 278
Schalling, M., 150
Scheffel, J. W., 987
Scheld, W. M., 1550
Schellekens, P. T. A., 1050
Schiffman, M., 1424
Schiller, J. T., 1424
Schmid, S., 1624
Schmidt, C. A., 976, 1748
Schmit, I., 487
Schoenbach, V. J., 99
Schollaardt, T., 1288
Schooley, R. T., 1833
Schoppel, K., 1748
Schröder, K., 2014
Schuchat, A., 1894
Schuitemaker, H., 854, 1106
Schulman, J. L., 579
Schulz, R.-J., 141
Schüpbach, J., 1089
Schurr, E., 150, 1521
Schuster, B. G., 1282
Schwander, S. K., 2069
Schwartz, I., 720
Schwarz, M. J., 1695
Schwebke, J. R., 1632
Sciberras, J., 187
Scott, D. R., 1424
Scott, J., 369
Sears, C. L., 167
Sebek, M. M. G. G., 726
Segura, A. M., 929
Segurado, A. A. C., 2077
Sei, S., 626
Seki, N., 880
Sekulovich, R. E., 970, 1700
Semba, R. D., 93
Semplici, F., 871
Séréni, D., 1342
SEROCO-HEMOCO-SEROGEST Study Groups, 920
Serwadda, D., 1316
Seth, P., 959
Sethi, S., 404
Sewankambo, N. K., 1316
Sexton, D. J., 900

Sfakianos, G., 1851
Sha, B. E., 61
Shah, A. R., 1351
Shah, K. V., 1316
Shamaei-Tousi, A., 1929
Shearer, G. M., 1682
Shearer, W. T., 1514
Sherertz, R. J., 1603
Sherlock, C. H., 1347
Sherman, M. E., 1424
Shi, Y., 950
Shikuma, C. M., 61
Shimizu, K., 1374
Shouval, D., 2018
Shuey, S., 268
Shutt, K. A., 1894
Sibille, Y., 1195
Siccardi, A. G., 871
Siliciano, R. F., 1827
Silsand, Y., 1
Silveira, A. M. S., 1665
Silvennoinen, E., 1771
Simeoni, E., 1411
Simmonds, P., 1748
Simmons, S. S., 2018
Simpson, A. J. H., 1878
Simpson, D. M., 61
Simpson, S. D., 762
Singer, W., 106
Singh, M., 225
Singh, U. B., 959
Singleton, R. J., 41
Sinh, D. X., 1288
Sinicco, A., 1018
Sinzger, C., 976
Sipsas, N. V., 2044
Sireci, G., 225
Skamene, E., 1521
Skinhøj, P., 551
Skoner, D. P., 10
Skowron, G., 1064
Slaoui, M., 1656
Smith, A. L. , 577
Smith, D., 320
Smith, M. D., 1878
Smith, N. A., 600
Snippe, H., 888
Snowden, K., 2086
Snoy, P. J., 521
Sobrinho, J. P., 1415
Soini, H., 1245
Sokoll, L. J., 93
Soldan, S. S., 685
Somasundaran, M., 1790
Sombardier, M.-N., 351
Sonderfan, A. J., 203
Sørensen, O., 1722
Sotiriou, J., 904
Spallek, R., 225
Spearman, P., 1122
Spector, S. A., 344
Speelman, P., 1878
Spengler, U., 1704
Spiegel, H. M. L., 359
Spielman, A., 2081
Spira, T. J., 1033
Spreghini, E., 156
Spritzler, J., 61
Squires, K., 659
Srinivas, S. R., 546
Ssengooba, F. P., 1436
St. Louis, M. E., 1159, 1624
Staeheli, P., 1695
Stager, C., 929
Stahl-Hennig, C., 1494
Stamm, W. E., 774
Stanberry, L. R., 203, 821
Standiford, H. C., 438
Stark, K., 2014
Staszewski, S., 530, 659
Steele, C., 802
Steere, A. C., 377
Steffen, R., 2053
Steigbigel, R., 659
Stein, D., 1064
Steiner, F., 1089
Stellbrink, H.-J., 1690
Stephens, D. S., 1894
Sterling, C. R., 1275
Sterling, T. R., 666
Sternberg, M., 1159
Stevens, D. L., 1921
Stolte, N., 1494
Stone, K., 1624
Straus, S. E., 586, 594
Strickler, H. D., 1682
Strieter, R., 1220
Strober, W., 586
Su, H., 1252
Su, R., 2064
Su, Y.-C., 2064
Sugita, S., 880
Sugiyama, T., 2048
Suharti, C., 176
Sullivan, A., 229, 1987
Sullivan, G. W., 1550
Sullivan, J. L., 1790
Sullivan, P. S., 1033
Sundar, S., 564
Sundsfjord, A., 1
Suriyanon, V., 337
Sutthent, R., 50
Suzuki, M., 122
Svanborg, C., 1220
Svenungsson, B., 542
Swiss HIV Cohort Study, 850, 1803
Swords, W. E., 1142
Tacconelli, E., 448
Tacket, C. O., 2056
Taguchi, C., 880
Taguchi, T., 1902
Taha, T. E. T., 93, 1838
Takahashi, M., 1750
Takeda, T., 1590, 1902
Tamm, M., 247
Tanaka, K., 1374
Tang, D. B., 1282
Tang, J., 299
Tang, Y.-W., 1324
Tansuphaswadikul, S., 87
Tanzman, E., 2023
Tao, P., 359
Tarkowski, A., 1370
Tarleton, R. L., 480
Tarone, R. E., 1424
Tarsia, P., 2074
Tartaglia, J., 290
Tashima, K. T., 862
Täuber, M. G., 896
Taylor, D. N., 2089
Taylor, T., 1742
Tembo, M., 1742
Templeton, A., 1025
ten Cate, H., 176
ten Cate, J. W., 176
Ten Haaft, P., 1494
Tenover, F. C., 1177
Terai, A., 1378
Terajima, M., 2030
Tesh, R. B., 966
Tesh, V. L., 1205
Thakrar, B., 607
Thakur, A., 1665
Thauvin, M., 526
Thauvin-Eliopoulos, C., 1177
Theodorou, I., 920
Theofan, G., 626, 641
Thiel, G., 247
Thomas, A. E., 1748
Thompson, M. L., 330
Thompson, W. W., 505
Thomson, B. J., 27
Thornton, C., 538
Tidwell, R. R., 2039
Tilles, J. G., 1338
Timmerman, J. A. B., 1267
Tinelli, C., 1827
Tiollais, P., 15
Titone, L., 225
Toé, L., 1394
Tomasik, Z., 1089
Tomee, J. F. C., 1267
Tompkins, M. B., 1503
Tompkins, W. A. F., 1503
Tonda, R., 1939
Toossi, Z., 2069
Torosantucci, A., 448
Torres, J. V., 206
Trabattoni, D., 871
Trapnell, C. B., 61
Travers, K. U., 1116
Treanor, J. J., 2023
Trejo, V., 1072
Trent HCV Study Group, 27
Trepka, M. J., 1214
Trepo, C., 2003
Trick, W. E., 391
Trigiani, E. R., 546
Troiani, L., 2039
Troop, M., 1096
Trubey, C. M., 1682
Tsai, C.-M., 747
Tsai, T.-J., 191
Tsaparidou, S., 904
Tshomba, Y., 2074
Tsiouris, J., 904
Tsou, J., 344
Tukesiga, E., 1403
Tulkens, P. M., 1195
Tumbarello, M., 448
Turgeon, F., 1597
Turgeon, P., 1597
Turner, G., 1742
Tuross, N., 2060
Tyndall, M. W., 1886
Tzioufas, A. G., 2044
Uchida, H., 1902
Udhayakumar, V., 1754
Ugen, K. E., 1351
Uhnoo, I., 2018
Ukita, M., 1750
Ulrich, R. G., 1365, 1370
Ulrichs, T., 141
Umlauft, F., 1452
Unadkat, J. D., 1536
Unnasch, T. R., 1394
Urbanek, M., 1452
van Amerongen, G., 1133
van Baalen, C. A., 1133
van Dam, E. M., 649
Van Damme, P., 2018
van der Hoeven, L., 93
van der Meer, J. W. M., 176, 1648
van der Poll, T., 1878
van Deventer, S. J. H., 1878
van Embden, J. D. A., 726, 1238
Van Ghelue, M., 1
van Gorp, E. C. M., 176
van Hattum, J., 2018
van Helden, P. D., 1608
Vanhems, P., 1803
Van Hoecke, C., 1656
van Lier, R. A. W., 1869
van Rie, A., 1608
van Rij, R. P., 854, 1106
van Soolingen, D., 726, 1238
van 't Wout, A. B., 854
van Wengen-Stevenhagen, A., 649
Varnier, O. E., 1089
Varrasso, A., 2009
Vatteroni, M. L., 838, 1411
Vaughn, D. W., 1429
Vaughn, T. N., 1994
Vecchiarelli, A., 1542
Veen, J., 726
Vella, S., 1018
Velleca, R., 285
Vellenga, E., 1267

Venet, A., 1342
Venkataraman, L., 1177
Venzon, D. J., 626
Verdrengh, M., 1370
Verheul, A. F. M., 888
Victor, T. C., 1608
Viebahn, R., 976
Vieira, V. S. D., 1153
Villa, L. L., 1415
Villa, M. L., 871
Villaseñor-Sierra, A., 1921
Vincent, J.-L., 1584
Violin, M., 285
Viriyavejakul, P., 1282
Visser, J., 854
Vitour, D., 574
Vizzard, J., 320
Vlahov, D., 666, 1018, 1025
Voelker, D. R., 2009
Voloshen, T., 1390
Volpi, A., 1747
von Bonsdorff, C.-H., 1771
Vonk, A. G., 1408
Voss, G., 1656
Vugia, D. J., 1361
Wabwire-Mangen, F., 1316
Wagner, L. J., 1080
Wahl, L. M., 1142
Wahl, M., 2018
Walker, B., 1827
Walker, D. H., 900
Walker, M. C., 290
Wallace, M. R., 641
Wallis, R. S., 2069
Walsek, C. M., 626
Walsh, D. S., 1282
Walsh, E. E., 268
Walter, E., 2018
Walter, S., 1186
Wan, P.-C. T., 621
Wang, F.-Z., 2035
Wang, J. B., 843
Wang, W.-C., 2064
Wang, Y., 1536
Wang, Z.-q., 1072
Wanger, A., 1245
Wanprapar, N., 50
Wara, D. W., 1080
Ward, J. I., 1569
Ward, M. J., 1616
Warren, R. M., 1608
Wasas, A. D., 1171
Wasi, C., 50
Wasserman, S. S., 1709
Watanabe, K., 1777
Waterman, S. H., 1361
Waters, D., 1487
Watts, D. H., 426
Wawer, M. J., 1316
Waziri, A., 685
Webb, E., 641
Webb, M., 896
Wedege, E., 242
Weidmann, E., 530
Weinberg, J. B., 1994
Weiner, D. B., 1351
Weinhold, K. J., 290, 1080
Weisfuse, I. B., 1159
Weiss, G., 1452
Weiss, H. L., 1632
Weiss, J. B., 1382
Weiss, L., 1057
Weiss, R. A., 600
Weisstein, A. E., 1025
Weitzberg, E., 542
Welles, S. L., 1487
Wennerholm, S., 2018
Were, W. A., 1436
Werner, S. B., 1361
Wertheim-van Dillen, P. M. E., 1869
Wetzler, L. M., 755, 762
Wharfe, G., 1487
Whitby, D., 600
White, M., 1584
White, N. J., 1288, 1878
Whitman, J. E., 1682
Whitmire, W., 1252
Whitmore, J., 1064
Wideroff, L., 1424
Wiedermann, C. J., 216
Wiegman, A., 1869
Wiklund, N. P., 542
Wilairatana, P., 1282
Wilfert, C., 99
Wilkinson, J., 68
Wilks, R. J., 1487
Willcocks, M. M., 514
Willems, B., 1597
Williams, A., 1777
Williams, S. W., 505
Wiltfang, J., 518
Wirth, D. F., 2081
Witkin, S. S., 912
Wohl, D. A., 61
Wolff, M., 290
Wong, C., 884
Wong, J. K., 1043
Wood, L. V., 626
Woods, C., 99
Woods, R., 35
Wormser, G. P., 720
Wright, D. C., 1939
Wright, D. J., 438
Wright, K. E., 521
Wright, P. F., 1080
Wright, R., 320
Wu, A. W., 61
Wuhib, T., 167
Wyld, R., 614
Xiao, L., 559
Xu, J., 626
Yaganehdoost, A., 1245
Yamada, A., 880
Yamaguchi, K., 880
Yamamoto, M., 122
Yamamoto, S., 1378
Yamanishi, K., 50
Yang, E., 1700
Yang, S. Y., 1072
Yano, S., 834
Yeaman, M. R., 1561
Yeh, C.-T., 992
Yerly, S., 850
Yip, B., 1347
Yirrell, D. L., 614
Yoder, K. E., 1386
Yokochi, T., 2048
Yoshida, O., 1378
Yoshida, T., 2048
Young, B., 570
Young, J. F., 35
Yu, X., 1569
Yu, X.-F., 1025
Yuri, K., 834
Zahradnik, J., 843
Zajac, D., 1390
Zanella, R. C., 1153
Zanghellini, F., 702
Zaunders, J. J., 68, 320
Zavattoni, M., 1320
Zayat, M. K., 56
Zeichner, S., 1682
Zhang, L., 480
Zhang, X.-Q., 1833
Zhang, Y.-J., 1466
Ziegler, M.-L., 935
Ziegler, T., 935

Subject Index

Abdominal infections, sepsis in, vs. tumor necrosis factor–α levels, 116
ABH blood group glycoconjugates, interactions with *Escherichia coli* heat-labile toxin, rabbit model, 419
Acquired immunodeficiency syndrome (*See* Human immunodeficiency virus infection [type 1 or unspecified])
ACTH (*See* Adrenocorticotropin)
α-Actinin, *Trichomonas vaginalis*, detection, 1727
Acyclovir
  for herpes simplex reactivation inhibition, in trigeminal ganglion, mouse model, 821
  for herpes simplex virus infections, in human immunodeficiency virus infection, failure, 487
  prophylactic
    in bone marrow transplantation, 571
    for varicella-zoster virus infections, cellular immunity in, 834
  resistance to, herpes simplex virus, 487
Adenosine receptor A_{1A}, synergy with rolipram, in meningitis, rat model, 1550
Adhesion
  Candida albicans, vitronectin receptors in, 156
  Plasmodium falciparum, in pregnancy, 464
Adhesion molecules, in infections, 176
Adrenocorticotropin, response to lipopolysaccharide, in human immunodeficiency virus infection, 106
Adult T cell leukemia/lymphoma
  natural history, proviral DNA levels in, 1487
  nosocomial respiratory syncytial virus infection outbreak in, 1686
African relapsing fever, *Borrelia crocidurae*, erythrocyte aggregation in, mouse model, 1929
Agammaglobulinemia, ganciclovir-resistant cytomegalovirus infections in, in pediatric patients, 491
AIDS (*See* Human immunodeficiency virus infection [type 1 or unspecified])
AIDS dementia complex, *CCR5* genotypes in, 854
Airway
  epithelial cells, interleukin induction in, by *Aspergillus fumigatus* proteases, 1267
  immunoglobulin administration in, in respiratory syncytial virus protection, mouse model, 1324
Alcohol abuse, streptococcal toxic shock syndrome risk in, 410
Amantadine, resistance to, influenza virus, 935
Amniocentesis, cytomegalovirus detection in, 1320
Amphotericin B
  in acquired immunity suppression, *Listeria monocytogenes*, mouse model, 1186
  cytokine induction by, 1408
  mechanism of action, in monocytes, 1259
Ampicillin
  Listeria monocytogenes intracellular growth effects, 1195
  in vancomycin-resistance promotion, 384
Ampicillin-sulbactam, in vancomycin-resistance promotion, 384
Amprenavir, for human immunodeficiency virus infection, α_1-acid glycoprotein concentration effects on, 1833
Anaerobes
  sepsis, vs. tumor necrosis factor–α levels, 116
  vaginal, nonoxynol-9 preparation effects on, 426
Ancylostoma caninum, vaccination, mouse model, 1674
Anemia
  in human immunodeficiency virus infection, erythropoietin autoantibodies in, 2044
  in malaria
    cytokine balance in, 1753
    hemoglobin levels in, 925
Anergy, T cell, in Kawasaki disease, 1869
Angiomatosis, bacillary, human herpesvirus 8 absent from, 1386
Animal models
  Aspergillus fumigatus pulmonary infections, interleukin-4 and, mouse, 1957
  atherosclerosis and *Chlamydia pneumoniae* infections, mouse, 238
  Bacillus decontamination with antimicrobial nanoemulsions, mouse, 1939
  Borrelia crocidurae infections, mouse, 1929
  Candida albicans infections, Fas-FasL interactions in, mouse, 1648
  Chagas' disease persistence, mouse, 480
  chlamydial genital infection treatment, mouse, 1252
  crossreactive antibodies to *Staphylococcus aureus* superantigens, mouse, 1365
  Cryptococcus neoformans infections
    pathophysiology, mouse, 1637
    treatment with monoclonal antibodies, mouse, 791
  Encephalitozoon cuniculi infections, 2086
  Escherichia coli heat-labile toxin response, rabbit, 419
  Escherichia coli infections, kidney pathology, mouse, 1374
  granulocytic ehrlichiosis pathogenesis, mouse, 546
  guanarito virus infections, cane mouse, 966
  Haemophilus influenzae mucosal vaccination, mouse, 122
  hepatitis C antibody response, chimpanzee, 987
  herpes simplex virus infections
    genital, protection with microbicide PRO 2000, mouse, 203
    reactivation in trigeminal ganglia, mouse, 821
    treatment, mouse, 594
  hookworm vaccination, mouse, 1674
  human immunodeficiency virus infection (*See also* Simian immunodeficiency virus infection)
    type 2
      cat, 1503
      macaque, 673
  interleukin-12 viral vaccine adjuvant, mouse, 940
  Listeria monocytogenes immunity suppressed by amphotericin B, mouse, 1186
  measles virus infection, virulence of strains in, macaque, 950
  meningitis, treatment with rolipram, rat, 1550
  meningococcal vaccination, mouse, 747
  mumps virus neurovirulence safety test, monkey, 521
  neisserial porin immune response, mouse, 755
  pelvic inflammatory disease, *Chlamydia trachomatis* heat-shock protein 60 antibody in, monkey, 774
  pertussis vaccination with respiratory syncytial virus challenge, mouse, 714
  pneumococcal meningitis pathophysiology, rat, 1164
  respiratory syncytial virus infections
    monoclonal antibodies
      mouse, 708
      rat, 35
    neutralization with Epstein-Barr virus antibodies, mouse, 268
    protection against, mouse, 1324
  S100 β protein in scrapie, hamster, 518
  schistosomiasis treatment, mouse, 454
  simian immunodeficiency virus infection
    nonprogressive, cytotoxic T cell decline in, macaque, 1133

virus replication in, BOB/GPR15 orphan receptor in, macaque, 1494
Staphylococcus aureus infections
endocarditis, rabbit, 1561
osteomyelitis pathogenesis, mouse, 1912
sepsis vaccination, mouse, 1370
streptococci group B vaccination, rabbit, 892
Streptococcus pneumoniae bacteremia, mouse, 133
T cell response to inactivated influenza virus, mouse, 579
tuberculosis genetic factors, mouse, 150
urinary tract infection resistance, mouse, 1220
vaginal candidiasis, macaque, 802
vancomycin resistance, mouse, 384
Venezuelan hemorrhagic fever, cane mouse, 966
visceral leishmaniasis treatment with doxorubicin and interferon-τ, mouse, 811
Yersinia pseudotuberculosis mitogen pathogenic effects, mouse, 1590
ANRS 053 trial, human immunodeficiency virus infection treatment with highly active antiretroviral therapy, 1342
Anthrax spores, decontamination, antimicrobial nanoemulsions for, mouse model, 1939
Antibiotics *(See specific antibiotics and diseases)*
Antibody(ies)
avidity maturation, after combination vaccination, 1390
Chlamydia trachomatis heat-shock protein 60, in pelvic inflammatory disease, monkey model, 774
Cryptococcus neoformans
glucuronoxylomannan, in children, 915
in meningitis, in human immunodeficiency virus infection, 1526
cytomegalovirus, in asymptomatic infection, 702
erythropoietin, in human immunodeficiency virus infection, 2044
Haemophilus influenzae, induction in mucosa immunization, mouse model, 122
heat-shock protein 60, *Chlamydia trachomatis*, human leukocyte antigen associations, 234
hepatitis C virus, chimpanzee model, 987
human immunodeficiency virus (*See* Human immunodeficiency virus, antibodies to)
polyspecific self-reactive, in T cell deletion, 1072
influenza virus, avian, in household and social contacts, 1763
monoclonal
for *Cryptococcus neoformans* infections, mouse model, 791
Epstein-Barr virus, in respiratory syncytial virus neutralization, mouse model, 268
respiratory syncytial virus
activity, 35
mouse model, 708, 1324
neutralizing
cytomegalovirus, in bone marrow transplantation, 1747
human immunodeficiency virus, 871
lack of, human immunodeficiency virus infection transmission and, 344
streptococcal, toxic shock syndrome risk and, 410
parvovirus B19, nonstructural protein type, vs. clinical outcome, 500
Staphylococcus aureus superantigens, mouse model, 1365
Streptococcus pneumoniae, assays for, mouse model, 133
Antibody-dependent cellular cytotoxicity, in severe immunodeficiency, in human immunodeficiency virus infection, 1338
Antigens
Coccidioides immitis, in different strains, 243
cytomegalovirus, T cell response to, in kidney transplantation, 247
hepatitis B virus, T cell response to, in vaccine therapy, 15
latent nuclear, human herpesvirus 8, polymorphism, 1466
p24, human immunodeficiency virus, monitoring, in pediatric patients, 1089
Plasmodium falciparum, in pregnancy and childhood, 464
Staphylococcus aureus, crossreactive antibodies to, mouse model, 1365
Antimony compounds, for leishmaniasis
cutaneous, 1735
resistance to, 564
Antiretroviral agents *(See also specific agents)*
for human immunodeficiency virus infection
$CD8^+$ anti–human immunodeficiency virus suppressor activity in, 68
clinical trials, 351
highly active (*See* Highly active antiretroviral therapy)
primary (acute), T cell partial normalization in, 320
Antisera, pneumococcal, in phagocytosis mediation, Fc, receptors and, 888
Aortic aneurysm, *Chlamydia pneumoniae* detection in, 2074
Aphthous ulcers, esophageal, in human immunodeficiency virus infection, treatment with thalidomide, 61
Apoptosis
endothelial cells, Shiga toxin effects on, 2048
epithelium-derived cells, *Escherichia coli* Shiga toxin effects on, 1902
in esophageal ulcers, in human immunodeficiency virus infection, 211
induction by *Trypanosoma cruzi trans*-sialidase, mouse model, 1398
macrophages, in *Mycobacterium avium* infections, interleukin-10 effects on, 1230
Arenaviruses, infections, natural history, cane mouse model, 966
Arthralgia, in o'nyong-nyong fever, 1436
Arthritis, rheumatoid, TT viremia in, 838
Ascitic fluid
cefotaxime and metabolites in, in spontaneous bacterial peritonitis treatment, 1597
hepatitis C virus replication in, quasispecies development in, 992
Aspergillus fumigatus
proteases, in interleukin induction, 1267
pulmonary infections, susceptibility to, interleukin-4 and, mouse model, 1957
Astroviruses, infections, epidemiology, in child care centers, 514
Atherosclerosis pathogenesis
Chlamydia pneumoniae infections and, 780, 2074
mouse model, 238
oxidized low-density lipoprotein
adhesion to CD36 receptor, 473
Chlamydia pneumoniae in, 780
Atovaquone, for *Pneumocystis carinii* pneumonia prevention, in human immunodeficiency virus infection, 369
Autoimmunity
in anemia, in human immunodeficiency virus infection, 2044
to *Trypanosoma cruzi*, mouse model, 480
Avidity maturation, after combination vaccination, 1390
Azithromycin
Listeria monocytogenes intracellular growth effects, 1195
for *Mycobacterium avium* infections, in human immunodeficiency virus infection, 229

B cells, in influenza virus immunity development, mouse model, 940
Bacillary angiomatosis, human herpesvirus 8 absent from, 1386

Bacillus, decontamination, antimicrobial nanoemulsions for, mouse model, 1939
Bacteremia
  emerging pathogen monitoring and, 87
  Mycobacterium avium, in human immunodeficiency virus infection, culture in, 438
  Neisseria meningitidis
    epidemiology, United States, 1894
    vaccination, mouse model, 747
  streptococcal, toxin-neutralizing antibodies in, 410
  Streptococcus pneumoniae
    mouse model, 133
    prolonged inflammation in, in elderly persons, 551
Bacterial overgrowth, cholera vaccine immunogenicity and, 1709
Bacterial vaginosis
  interleukin-1 receptor antagonist gene polymorphisms and, 912
  microbiology, vs. sexual behavior, 1632
  sexually transmitted disease risk and, 1863
Bartonella
  infections, human herpesvirus 8 absent from, 1386
  rat reservoir for, 220
BCTP and BCTP 410 antimicrobial nanoemulsions, for *Bacillus* decontamination, mouse model, 1939
Biocides, for *Bacillus* decontamination, mouse model, 1939
Biopsy, small intestine, in microsporidiosis, in human immunodeficiency virus infection, 929
BK virus infections, in systemic lupus erythematosus, 1
Bladder infections, resistance to, neutrophil recruitment in, mouse model, 1220
Blood culture
  for emerging infections, 87
  Mycobacterium avium, in human immunodeficiency virus infection, 438
Blood donor population, human T cell lymphotropic virus type I and type II antibodies in, 1777
Bloodstream infections (*See also* Bacteremia)
  emerging pathogen monitoring and, 87
BOB/GPR15 orphan receptor, in simian immunodeficiency virus replication, macaque model, 1494
Bone, archaeologic specimen, *Treponema pallidum* identification in, 2060
Bone marrow
  culture, *Mycobacterium avium*, in human immunodeficiency virus infection, 438
  transplantation
    cytomegalovirus neutralizing antibody in, 1747
    ganciclovir-resistant cytomegalovirus infections in, in pediatric patients, 491
    viral infection prophylaxis in, 571
Bordetella pertussis, vaccination (*See also* Diphtheria-tetanus-pertussis vaccination)
  acellular, in adults, 397
  respiratory syncytial virus response in, mouse model, 714
Borna disease virus, in neuropsychiatric disorders, 1695
Borrelia crocidurae, infections, erythrocyte aggregation in, mouse model, 1929
Borreliosis (*See* Lyme disease)
Bovine hyperimmune milk product, for enterotoxigenic *Escherichia coli* diarrhea prevention, 2056
Brain
  Borna disease virus in, 1695
  Borrelia crocidurae infections, mouse model, 1929
  endothelial cells, Shiga toxin interactions with, 1205
  malaria
    cytokine expression in, 1742
    pathogenesis, cytokines in, 1288
    resistance in, chloroquine, epidemiology, Saudi Arabia, 1738
  pork tapeworm infection, serologic testing for, 1307
Breast feeding, human immunodeficiency virus transmission in, 93
8-Bromoadenosine 3′,5′-cyclic monophosphate, in Shiga toxin interactions with brain endothelial cells, 1205
Bronchitis, chronic, *Haemophilus influenzae* colonization in, 404
Burkholderia pseudomallei, infections, cytokine levels in, 1878
n-Butyric acid, in Shiga toxin interactions with brain endothelial cells, 1205

CAESAR study, of hepatitis B–human immunodeficiency virus coinfection, 607
Calcium, in amphotericin B mechanism of action, 1259
Calmodulin, in amphotericin B mechanism of action, 1259
Canarypox, in vaccine preparation
  cytomegalovirus, 843
  human immunodeficiency virus, 290, 1122
Cancer, cervical, human papillomavirus infection epidemiology and, Brazil, 1415
Candida, colonization, in human immunodeficiency virus infection, vs. viral load, 534
Candida albicans
  infections
    in human immunodeficiency virus infection, protease inhibitor effects on, 448
    systemic, Fas-FasL interactions in, mouse model, 1648
  sepsis, vs. tumor necrosis factor–α levels, 116
  vitronectin receptors on, 156
Candidiasis, vaginal, macaque model, 802
Cantaloupes, *Salmonella saphra* infections from, 1361
Castleman's disease, interleukin-6 production in, 824
Catheter-related infections, vascular, neutrophil chemotaxis on device surfaces, 1603
CCRs (chemokine receptors) (*See* Chemokines and chemokine receptors)
CD4 molecule (*See* T cells, CD4)
CD8 molecule (*See* T cells, CD8)
CD36 molecule, *Plasmodium falciparum*–infected erythrocyte adhesion to, 473
Cefotaxime, for spontaneous bacterial peritonitis, 1597
Cefotetan, in vancomycin-resistance promotion, 384
Ceftriaxone, for Lyme encephalopathy, 377
Cellular immune response (*See also* T cells)
  to *Candida albicans*, Fas-FasL interactions in, mouse model, 1648
  to cytomegalovirus, 702
    in kidney transplantation, 247
  to dengue virus, 1429
  to hepatitis C virus, 1452
  in highly active antiretroviral therapy, for human immunodeficiency virus infection, 76
  to human herpesvirus 8, in homosexual men, 1682
  to human immunodeficiency virus
    with early treatment, 1827
    in hemophilia cohort, 1790
    immunogen, 641
  in Kawasaki disease, 1869
  to malaria vaccine, mechanisms, 1656
  to neisserial porins, 762
  in tuberculosis, 2069
  to varicella-zoster virus, after acyclovir prophylaxis, 834

Cerebral malaria
cytokine expression in, 1742
pathogenesis, cytokines in, 1288
resistance in, chloroquine, epidemiology, Saudi Arabia, 1738
Cerebrospinal fluid
chemokines in, in human immunodeficiency virus infection, vs. cognitive impairment, 310
human immunodeficiency virus in, efavirenz effects on, 862
JC virus in, in progressive multifocal leukoencephalopathy, in human immunodeficiency virus infection, 1690
peroxynitrite in, in pneumococcal meningitis, rat model, 1164
Cervix
human papillomavirus infections, epidemiology, Brazil, 1415
squamous intraepithelial lesions, human papillomavirus seroreactivity in, 1424
cg2 gene, *Plasmodium falciparum,* polymorphism, 1979
Chagas' disease
parasite persistence in, mouse model, 480
trans-sialidase, apoptosis induction, mouse model, 1398
Chancroid
testing for, in genital ulcer disease, 1382
treatment, 1886
Chemokines and chemokine receptors
in *Cryptococcus neoformans* infection defense, mouse model, 1637
in human immunodeficiency virus infection
in cerebrospinal fluid, vs. cognitive impairment, 310
mutations and polymorphisms
AIDS dementia complex and, 854
progression and, 1096, 1106
stromal-derived factor 1, 285
toxoplasmosis risk and, 920
transmission and, 614
production, 858
in influenza, zanamivir effects on, 586
in simian immunodeficiency virus infection, BOB/GPR15 orphan receptor use with, macaque model, 1494
Chemotaxis, neutrophil, on catheter surfaces, 1603
Chemotherapy, streptococcal toxic shock syndrome risk in, 410
Chickenpox
acyclovir prophylaxis for, cellular immunity in, 834
zoster in, in human immunodeficiency virus infection, 1784
Children (*See* Pediatric patients)
Chlamydia pneumoniae, infections
atherosclerosis and, 2074
mouse model, 238
low-density lipoprotein oxidation and, 780
Chlamydia trachomatis
genital infections
testing for, 1382
treatment, mouse model, 1252
heat-shock protein 60 antibody
human leukocyte antigen associations, 234
in pelvic inflammatory disease, monkey model, 774
Chlamydial infections, epidemiology, risk behaviors and, urban adolescent females, 1624
Chloroquine
for malaria, vs. tafenoquine, 1282
resistance to, *Plasmodium falciparum,* 1738, 1979
Cholera, vaccination, small bowel bacterial overgrowth and, 1709
Chronic obstructive pulmonary disease, *Haemophilus influenzae* colonization in, 404
Ciprofloxacin
for chancroid, 1886
resistance to, streptococci, 555
Circumcision, human immunodeficiency virus infection transmission and, 330
Cirrhosis
in hepatitis C, pathogenesis, 1412
TT viremia in, 838
Citrobacter, resistance in, trimethoprim-sulfamethoxazole, 1809
Clindamycin, in vancomycin-resistance promotion, 384
Coagulation disorders, infections and, 176
Coccidioides immitis
antigen, in different strains, 243
vaccination, 243
Cognitive impairment
in human immunodeficiency virus infection, cerebrospinal fluid chemokine levels and, 310
in Lyme disease, treatment with ceftriaxone, 377
Collectins, binding to respiratory syncytial virus fusion glycoprotein, 2009
Colon, epithelial cells, *Yersinia pseudotuberculosis* mitogen pathogenic effects on, mouse model, 1590
Colonization
Candida, in human immunodeficiency virus infection, vs. viral load, 534
Haemophilus influenzae
in chronic obstructive pulmonary disease, 404
after mass vaccination, 1153
after *Haemophilus influenzae* vaccination, Brazil, 1153
Lactobacillus, vaginal, species identification, population demographics and, 1950
after pneumococcal vaccination, nonavalent conjugate, 1171
Staphylococcus aureus, nasal, in human immunodeficiency virus infection, eradication, 896
vaginal
interleukin-1 receptor antagonist gene polymorphisms and, 912
nonoxynol-9 preparation effects on, 426
vancomycin-resistant enterococci
from interfacility patient transfer, 391
parenteral antibiotic effects on, 384
Complement receptor, impairment, in human immunodeficiency virus infection, 1542
Congenital infections (*See* Human immunodeficiency virus infection [type 1 or unspecified], transmission, perinatal; Neonatal infections)
Cortisol, response to lipopolysaccharide, in human immunodeficiency virus infection, 106
Counseling, on human immunodeficiency virus infection, in women, 99
Creutzfeldt-Jakob disease, animal models for, 518
Cryptococcus neoformans
capsular polysaccharide glucuronoxylomannan, antibodies to, in children, 915
fungemia, emerging pathogen monitoring and, 87
infections
in human immunodeficiency virus infection, immune activation induced by, 559
smoking and, iron role in, 1412
treatment, 791
neutrophil response to, in human immunodeficiency virus infection, 1542
Cryptosporidium parvum
infections, epidemiology, Brazil, 167
virulence, variation among isolates, 1275
Culture
blood
for emerging infections, 87

Mycobacterium avium, in human immunodeficiency virus infection, 438
bone marrow, *Mycobacterium avium,* in human immunodeficiency virus infection, 438
Cutaneous leishmaniasis
T cell response in, 1731
treatment, 1735
Cysticercosis, serologic testing for, 1307
Cytokines *(See also specific cytokines)*
amphotericin B and, 1408
in *Candida albicans* infections, Fas-FasL interactions in, mouse model, 1648
in cerebral malaria, 1742
in hepatitis C, 1412, 1704
in human immunodeficiency virus infection, lipopolysaccharide response, 106
in influenza, 10
zanamivir effects on, 586
Listeria monocytogenes intracellular growth effects, 1195
in malaria
in anemia, 1753
pathogenesis and prognosis, 1288
in pregnancy, intrauterine growth retardation in, 1987
in mucosal *Haemophilus influenzae* immunization, mouse model, 122
in pneumococcal infections, in elderly persons, 551
in sepsis, 908
in Shiga toxin interactions with brain endothelial cells, 1205
Cytomegalovirus
detection, in fetus, 1320
infections
in human immunodeficiency virus infection
esophageal, 211
highly active antiretroviral therapy effects on, 847
prophylaxis, 571
valacyclovir for, 695
in kidney transplantation, predictive markers for, 195
neutralizing antibody in, in bone marrow transplantation, 1747
in pregnancy
diagnosis, 1320
viral measurement in, 2035
primary, asymptomatic, 702
targeted to hepatocytes, 976
resistance in, ganciclovir, 491
T cell immunity to, in kidney transplantation, 247
vaccination
canarypox-based, 843
glycoprotein B subunit, 1700
subunit, 970

Dapsone, resistance to, *Pneumocystis carinii,* 1969
Death (*See* Mortality)
Dehydroepiandrosterone sulfate, response to lipopolysaccharide, in human immunodeficiency virus infection, 106
Dementia, in human immunodeficiency virus infection
CCR5 genotypes in, 854
cerebrospinal fluid chemokine levels and, 310
Dengue hemorrhagic fever, CD69 expression in, in pediatric patients, 1429
Dengue virus, type 2, molecular evolution, 959
Desacetyl-cefotaxime, measurement, in spontaneous bacterial peritonitis treatment, 1597
Detergents, in antimicrobial nanoemulsions, for *Bacillus* decontamination, mouse model, 1939

Diarrhea
astrovirus, epidemiology, in child care centers, 514
Cryptosporidium
clinical variation among isolates, 1275
epidemiology, Brazil, 167
enterotoxigenic *Escherichia coli*
bovine hyperimmune milk product activity in, 2056
organism identification in, 2053
microsporidial, in human immunodeficiency virus infection, 2006
Norwalk-like virus, from drinking water, 1771
Didanosine, for human immunodeficiency virus infection
clinical trials, 351
pharmacokinetics, in mothers and neonates, 1536
resistance to, 1043
before seroconversion, 1827
Diethylcarbamazine, for onchocerciasis, dermatitis after, 1394
Dihydropteroate synthase, *Pneumocystis carinii,* mutations, 1969
Diphtheria-tetanus-pertussis vaccination
Haemophilus influenzae vaccine with
colonization rate after, 1153
immunologic memory induction by, 538
Haemophilus influenzae–hepatitis B vaccine with, avidity maturation after, 1390
Disseminated intravascular coagulation, in infections, 176
DNA analysis
for astrovirus, 514
for *Chlamydia pneumoniae,* atherosclerosis and, 2074
for *Lactobacillus* species, in vaginal colonization, 1950
for simian virus 40, 884
for *Taenia solium,* in neurocysticercosis, 1307
for *Treponema pallidum* in archaeologic skeletal specimen, 2060
DNA polymerase, herpes simplex virus, in drug resistance, 487
DNA vaccines, schistosomiasis, mouse model, 454
Dot-blot hybridization, for *Mycobacterium tuberculosis,* multidrug-resistant, 1608
Doxorubicin, for visceral leishmaniasis, mouse model, 811
Doxycycline, for chlamydial genital infections, mouse model, 1252
Drinking water, diseases from (*See* Waterborne diseases)
Drug abuse, intravenous, human immunodeficiency virus genetic evolution in, 1025
Drug resistance
acyclovir, herpes simplex virus, 487
amantadine, influenza virus, 935
antimony compounds, *Leishmania donovani,* 564
chloroquine, *Plasmodium falciparum,* 1738, 1979
cytomegalovirus, ganciclovir, 491
dapsone, *Pneumocystis carinii,* 1969
didanosine, 1043
enterococci, vancomycin, from interfacility patient transfer, 391
Enterococcus faecium, vancomycin
epidemiology, 1177
mouse model, 384
Escherichia coli, trimethoprim-sulfamethoxazole, 1809
fluoroquinolones, streptococci, 555
foscarnet, herpes simplex virus, 487
ganciclovir, cytomegalovirus, 491
herpes simplex virus
acyclovir, 487
foscarnet, 487
human immunodeficiency virus, 865
in injection drug users, 1025
reverse transcriptase sites in, 1043
influenza virus, rimantadine, 935
lamivudine, 865

Leishmania donovani, antimony compounds, 564
malaria
chloroquine, 1979
mefloquine, 2077
mefloquine, *Plasmodium falciparum,* 2077
multiple
pneumococci *(Streptococcus pneumoniae),* 1577
tuberculosis, transmission, 1608
Mycobacterium tuberculosis
mutations in, 1751
transmission, 1608
nelfinavir, 865
nevirapine, 1043
Plasmodium falciparum
chloroquine, 1979
mefloquine, 2077
pneumococci *(Streptococcus pneumoniae),* study methods for, 1577
Pneumocystis carinii, 1969
rimantadine, influenza virus, 935
Staphylococcus aureus, trimethoprim-sulfamethoxazole, 1809
streptococci, fluoroquinolones, 555
trimethoprim-sulfamethoxazole, 1809
Pneumocystis carinii, 1969
tuberculosis
mutations in, 1751
transmission, 1608
vancomycin, enterococci
epidemiology, 1177
from interfacility patient transfer, 391
mouse model, 384
zidovudine, 99, 865, 1043

Efavirenz, for human immunodeficiency virus infection, 862
Eggs, *Salmonella enterica* enteritis from, 1214
Ehrlichiosis
epidemiology, North Carolina, 900
granulocytic, pathogenesis, mouse model, 546
Elderly persons, pneumococcal infections in, prolonged inflammation in, 551
ELISA (*See* Enzyme-linked immunosorbent assay)
Emerging infections, bloodstream, sentinels for, 87
emm1 gene, streptococcus group A, in opsonophagocytosis susceptibility, 1921
Emulsions, for *Bacillus* decontamination, mouse model, 1939
Encephalitozoon cuniculi, infections, in dogs and humans, 2086
Encephalitozoon intestinalis, infections, in human immunodeficiency virus infection, 2006
Encephalopathy, Lyme, treatment with ceftriaxone, 377
Endocarditis, *Staphylococcus aureus,* thrombin-induced platelet microbicidal protein-1 in, rabbit model, 1561
Endothelial cells
Shiga toxin interactions with, 1205, 2048
viral injury, coagulation disorders in, 176
Endotoxin (*See* Lipopolysaccharide)
Enteritis (*See* Gastroenteritis)
Enterobacter, resistance in, trimethoprim-sulfamethoxazole, 1809
Enterococci
resistance in, vancomycin, from interfacility patient transfer, 391
sepsis, vs. tumor necrosis factor–α levels, 116
vaginal, nonoxynol-9 preparation effects on, 426
Enterococcus faecium, resistance in, vancomycin
epidemiology, 1177
mouse model, 384
Enterocytozoon bieneusi, infections, in human immunodeficiency virus infection, 2006
Enterotoxins
Escherichia coli, ABH glycoconjugate interactions with, rabbit model, 419
Staphylococcus aureus, vaccination with, mouse model, 1365, 1370
env gene, human immunodeficiency virus, mutations, in injection drug users, 1025
Env pseudovirions, canarypox, in human immunodeficiency virus vaccine, 1122
Envelope protein, hepatitis C virus
antibody response to, chimpanzee model, 987
detection, 1328
Enzyme-linked immunosorbent assay
amplification-boosted, for p24 antigen, human immunodeficiency virus, 1089
for pneumococcal vaccine response evaluation, 1569
for *Trichomonas vaginalis* α-actinin, 1727
Eosinophil(s), recruitment, in onchocerciasis treatment with diethylcarbamazine, 1394
Eotaxin, *Onchocerca volvulus,* in dermatitis, after diethylcarbamazine application, 1394
Epidemics
dengue virus infections, type 2, molecular evolution, 959
malaria, genetic characterization, Yanomami Amerindians, 2081
typhoid fever, vaccination in, 2089
Epidemiology
astrovirus infection, in child care centers, 514
avian influenza virus, Hong Kong 1997, 505
chlamydial infections, risk behaviors and, urban adolescent females, 1624
Cryptosporidium infections, Brazil, 167
Enterococcus faecium, vancomycin-resistant, 1177
Helicobacter pylori, in couples, 2064
hepatitis A, South Texas children, 509
herpes simplex virus type 2 infections
neonatal, California, 199
urban adolescent females, 1624
Zimbabwe, 1459
human herpesvirus 8 infections
transmission, vs. sexual orientation, 600
in homosexual men, United States, 1010
human immunodeficiency virus infection
circumcision effects on, 330
in women, North Carolina, 99
human papillomavirus infections, cervical, Brazil, 1415
human T cell lymphotropic virus type I and type II infections, United States, 1777
influenza virus, rimantadine-resistant, 935
malaria
chloroquine-resistant, Saudi Arabia, 1738
genetic characterization, Yanomami Amerindians, 2081
meningococcal disease, United States, 1894
mumps virus genotypes, United Kingdom, 829
Neisseria gonorrhoeae infections, urban adolescent females, 1624
Norwalk-like virus gastroenteritis, Finland, 1771
o'nyong-nyong fever, Uganda, 1436
respiratory syncytial virus infections
Alaskan native children, 41
nosocomial, molecular characterization, 1686
Salmonella enterica enteritis, Wisconsin, 1214
Salmonella saphra, from Mexican cantaloupes, 1361
sexually transmitted diseases
circumcision effects on, 330

risk behaviors and, urban adolescent females, 1624
simian virus 40, in pediatric patients, 884
syphilis, jailed women in New York, 1159
tickborne diseases, North Carolina, 900
trichomoniasis, urban adolescent females, 1624
TT virus, 1748
Italy, 838
tuberculosis
in human immunodeficiency virus infection, barhopping and, 1245
multidrug-resistant, South Africa, 1608
Netherlands, 726
zoster, in human immunodeficiency virus infection, 1784
Epithelial cells
airway, interleukin induction in, by *Aspergillus fumigatus* proteases, 1267
injury, *Haemophilus influenzae*, 737
Epithelium-derived cells, pulmonary, *Escherichia coli* Shiga toxin effects on, 1902
Epstein-Barr virus
antibodies to, in respiratory syncytial virus neutralization, mouse model, 268
infections, susceptibility to, interleukin-10 gene polymorphism in, 496
Errata
endotoxin effects (1999;179:1278), 576
hepatitis B vaccine (1999;180:15), 1756
human herpesvirus 8 polymorphism (1999;180:1466), 1756
human immunodeficiency virus infection transmission (1999;180:337), 1756
immune response to *Schistosoma mansoni* antigens (1999;180:1665), 2092
Erysipelas, streptococcal, toxin-neutralizing antibodies in, 410
Erythrocytes
aggregation, in *Borrelia crocidurae* infections, mouse model, 1929
Plasmodium falciparum in, adhesion to CD36 receptor, 473
Erythromycin, for chancroid, 1886
Erythropoietin, antibodies to, in human immunodeficiency virus infection, 2044
Escherichia coli
bacteremia, emerging pathogen monitoring and, 87
enterotoxigenic
identification, in travelers' diarrhea, 2053
infections, bovine hyperimmune milk product activity in, 2056
heat-labile toxin, response, ABH glycoconjugates in, rabbit model, 419
infections, kidney pathology in, mouse model, 1374
prostatitis, virulence characteristics, 1378
resistance in, trimethoprim-sulfamethoxazole, 1809
sepsis, vs. tumor necrosis factor–α levels, 116
Shiga toxins
action on pulmonary epithelium–derived cells, 1902
endothelial cell apoptosis from, 2048
urinary tract infections
in neonates, 904
resistance to, mouse model, 1220
vaginal, nonoxynol-9 preparation effects on, 426
Esophagus, ulcers, in human immunodeficiency virus infection
pathogenesis, 211
treatment with thalidomide, 61
Exotoxins, pyrogenic, in streptococcal toxic shock syndrome, 410

Famciclovir, for herpes simplex virus infections, mouse model, 594
Fas protein
FasL interactions with, in *Candida albicans* systemic infection defense, mouse model, 1648
in tuberculosis resistance, 141
Fas receptors, up-regulation, in esophageal ulcers, in human immunodeficiency virus infection, 211
Fc_γ receptor
function, in human immunodeficiency virus infection, 1542
polymorphisms, pneumococcal phagocytosis and, 888
Feline immunodeficiency virus, CD8 T cell population in, L-selectin–negative, 1503
Fetus
cytomegalovirus detection in, 1320
growth retardation in, in maternal malaria, 1987
human herpesvirus 6 infections, 2035
Fever
bloodstream infections in, emerging pathogen monitoring and, 87
hemorrhagic
coagulation disorders and, 176
dengue, CD69 expression in, in pediatric patients, 1429
Venezuelan, cane mouse model, 966
o'nyong-nyong, epidemiology, Uganda, 1436
relapsing, *Borrelia crocidurae*, erythrocyte aggregation in, mouse model, 1929
spotted, epidemiology, North Carolina, 900
in tick bite, infections associated with, epidemiology, North Carolina, 900
Fibrinolysis, defects of, in infections, 176
Filariasis, *Mansonella streptocerca*, ivermectin for, 1403
Fluoroquinolones, resistance to, streptococci, 555
Foodborne diseases
Salmonella enterica enteritis, 1214
Salmonella saphra infections, 1361
Staphylococcus aureus, vaccination, mouse model, 1365
Foscarnet, for herpes simplex virus infections
in human immunodeficiency virus infection, failure, 487
resistance to, 487
Fungemia, emerging pathogen monitoring and, 87
Fungi, sepsis, vs. tumor necrosis factor–α levels, 116

Gag pseudovirions, canarypox, in human immunodeficiency virus vaccine, 1122
Ganciclovir
prophylactic, in bone marrow transplantation, 571
resistance to, cytomegalovirus, 491
Gardnerella vaginalis, nonoxynol-9 preparation effects on, 426
Gastritis, *Helicobacter pylori* morphology in, nitric oxide effects on, 1713
Gastroenteritis
diarrhea in (*See* Diarrhea)
nitric oxide production in, 542
Norwalk-like virus, from drinking water, 1771
Salmonella enterica, epidemiology, Wisconsin, 1214
Salmonella saphra, outbreak, 1361
Yersinia pseudotuberculosis, colonic epithelial pathophysiology in, mouse model, 1590
GB virus C (hepatitis G virus), infections
in hemodialysis, 191
human immunodeficiency virus infection in, 1334
Gender differences
in human immunodeficiency virus load, 666
in periportal fibrosis susceptibility, in schistosomiasis, 1298
Genetic factors
in *Chlamydia trachomatis* infections, 234
in periportal fibrosis susceptibility, in schistosomiasis, 1298

in tuberculosis, mouse model, 150
in vaginal colonization, 912
Genital tract infections
chlamydial, treatment, mouse model, 1252
herpes simplex virus (*See* Herpes simplex virus [type 2])
human papillomavirus, hybrid capture assay for, 1316
pelvic inflammatory disease, *Chlamydia trachomatis*, monkey model, 774
sepsis in, vs. tumor necrosis factor–α levels, 116
ulcers
microbiology, 1382
treatment, 1886
Glomerular lesions, in *Escherichia coli* infections, mouse model, 1374
Glucuronoxylomannan, *Cryptococcus neoformans*, antibodies to, in children, 915
Glycoconjugates
ABH blood group, interactions with *Escherichia coli* heat-labile toxin, rabbit model, 419
in vaccines, streptococci group B, rabbit model, 892
Glycoprotein(s)
cytomegalovirus, in vaccine preparation, 970
in human immunodeficiency virus infection, protease inhibitor efficacy and, 1833
respiratory syncytial virus, surfactant protein A binding to, 2009
Gonorrhea (*See Neisseria gonorrhoeae*, infections)
Granules, specific, neutrophil, YKL-40 protein, in pneumonia, 1722
Granulocyte colony-stimulating factor, for human immunodeficiency virus infection, 1819
Granulocyte-macrophage colony-stimulating factor
for cutaneous leishmaniasis, 1735
as hepatitis B virus vaccination adjuvant, 2023
for human immunodeficiency virus infection, 1064
for *Mycobacterium avium* infections, in human immunodeficiency virus infection, 229
Granulocytic ehrlichiosis, pathogenesis, mouse model, 546
Growth retardation, intrauterine, in maternal malaria, 1987
Guanarito virus, infections, natural history, cane mouse model, 966
gyr genes, in fluoroquinolone resistance transfer, 555

HAART (*See* Highly active antiretroviral therapy)
Haemophilus ducreyi, infections
testing for, 1382
treatment, 1886
Haemophilus influenzae
colonization, in chronic obstructive pulmonary disease, 404
nasopharyngeal epithelial injury by, 737
vaccination
combination, avidity maturation after, 1390
in combination vaccine, 538
herd effect, Brazil, 1153
mucosal, mouse model, 122
Hantavirus pulmonary syndrome, viral load in, 2030
Heat-shock protein 60 antibody, *Chlamydia trachomatis*
human leukocyte antigen associations, 234
in pelvic inflammatory disease, monkey model, 774
Helicobacter pylori
epidemiology, in couples, 2064
infections, in pediatric patients, paternal and maternal infection status and, 1407
morphology, nitric oxide effects on, 1713
Hematogenous dissemination, *Borrelia burgdorferi*, subtypes associated with, 720
Hematopoietic progenitor cells, granulocyte colony-stimulating factor effects on, in human immunodeficiency virus infection, 1819
Hemodialysis, GB virus C infection in, 191
Hemoglobin, in malaria, microcytosis and thalassemia effects on, 925
Hemolytic uremic syndrome
endothelial cell apoptosis in, 2048
in infections, 176
pulmonary epithelium–derived cell apoptosis in, 1902
Hemophilia
human immunodeficiency virus infection in
hepatitis C with, highly active antiretroviral therapy, 2027
nonprogression, 1790
zoster incidence in, 1784
TT viremia in, 838
Hemorrhage, in infections, 176
Hemorrhagic fever
coagulation disorders and, 176
dengue, CD69 expression in, in pediatric patients, 1429
Venezuelan, natural history, cane mouse model, 966
Hemostasis, in infections, 176
Hemozoin, placental, in malaria, 1987
Hepatitis A virus
infections, epidemiology, South Texas children, 509
vaccination
combined with hepatitis B virus vaccination, immunologic interference in, 2018
in transplantation, 2014
Hepatitis B virus
infections
chronic, treatment, vaccine therapy in, 15
epidemiology, urban adolescent females, 1624
human immunodeficiency virus infection with, treatment, 607
mutations, naturally occurring, 1444
vaccination
combination
avidity maturation after, 1390
with hepatitis A virus vaccination, immunologic interference in, 2018
granulocyte-macrophage colony-stimulating factor with, 2023
T cell proliferative responses in, 15
viral load, in lamivudine treatment, 1757
YMDD variants, 1757
Hepatitis C virus
envelope protein
antibody response to, chimpanzee model, 987
detection, 1328
infections
antibody response in, chimpanzee model, 987
in human immunodeficiency virus infection
highly active antiretroviral therapy, 2027
protease inhibitor effects on, 574
intrahepatic cytokine expression in, 1704
MxA protein induction in, 262
pathogenesis, 1452
treatment, interferon-α, 1411
TT virus and, 27, 838
mutations, interferon effects on, 1001
quasispecies
in ascitic fluid, 992
interferon effects on, 1001
replication, in ascitic mononuclear cells, quasispecies development in, 992

vaccination, envelope protein in, 1328
Hepatitis G virus (GB virus C), infections
in hemodialysis, 191
human immunodeficiency virus infection in, 1334
Hepatocytes, as cytomegalovirus targets, 976
Herd effect, *Haemophilus influenzae* vaccination, Brazil, 1153
Herpes simplex virus (type 1 or unspecified)
infections
in human immunodeficiency virus infection, treatment failure in, 487
neonatal, epidemiology, California, 199
treatment, mouse model, 594
reactivation, in trigeminal ganglion, mouse model, 821
Herpes simplex virus (type 2), genital infections
epidemiology
urban adolescent females, 1624
Zimbabwe, 1459
protection with microbicide PRO 2000, mouse model, 203
testing for, 1382
transmission, to neonates, 199
treatment, 1886
Herpes zoster, epidemiology, in human immunodeficiency virus infection, 1784
Herpesviruses (*See specific viruses, e.g.,* Human herpesvirus 8)
Highly active antiretroviral therapy, for human immunodeficiency virus infection
advanced, 659
anticandidal activity, 448
$CD8^+$ anti–human immunodeficiency virus suppressor activity, 68
cytomegalovirus viremia decrease in, 847
failure, 568
with hepatitis C, 2027
hepatitis C viremia disappearance in, 574
interleukin-1 with, 56
interleukin-2 production restoration in, 1057
in pediatric patients, 359
primary, 1342
T cell reconstitution in, 76
viral rebound in, 530
Hippocampus, degeneration of, Borna disease virus in, 1695
Histoplasma capsulatum, fungemia, emerging pathogen monitoring and, 87
HIV infection (*See* Human immunodeficiency virus infection [type 1 or unspecified])
Homosexual population, human immunodeficiency virus infection in
chemokine receptor polymorphisms in, 1096, 1106
human herpesvirus 8 infections in, 1010
immune response to, 1682
transmission, 600
JC virus DNA in, 1690
Kaposi's sarcoma in, 1010
progression, 1096, 1106
human leukocyte antigens in, 299
viral load in, longitudinal study, 1018
zoster incidence, 1784
Hookworm, vaccination, mouse model, 1674
Host defense (*See also* Cellular immune response; Humoral immune response; Immune response)
Candida albicans, Fas-FasL interactions in, mouse model, 1648
respiratory syncytial virus, surfactant protein binding to fusion glycoprotein, 2009
in sepsis, 908
streptococci group A, 1718
Human granulocytic ehrlichiosis
epidemiology, North Carolina, 900
pathogenesis, mouse model, 546
Human herpesvirus 6, infections
in human immunodeficiency virus infection, in pediatric patients, 50
interleukin-6 expression in, 824
reactivation during pregnancy, 2035
Human herpesvirus 8 (*See also* Kaposi's sarcoma)
cellular immune response to, in homosexual men, 1682
infections
with dual genotypes, 1466
epidemics, among homosexual men, United States, 1010
sexual transmission, 600
latent nuclear antigen, polymorphism, 1466
testing for, in bacillary angiomatosis, 1386
Human immunodeficiency virus (type 1 or unspecified)
antibodies to
failure to develop, 1033
neutralizing, mother-to-infant transmission and, 344
polyspecific self-reactive, in T cell deletion, 1072
in sexually exposed seronegative persons, 871
DNA, in acute infection, potent treatment effects on, T cell subsets after, 320
exposure to, seronegativity in, 871
mutations, in injection drug users, 1025
non–syncytium-inducing, progression and, 1106
replication
Mycobacterium avium effects on, 1142
phosphoantigen-reactive T cell suppression, 858
resistance to, *NRAMP1* gene variants in, 1521
RNA
vs. *Candida* colonization, 534
cell-associated, as lymph node viral load indicator, 850
during first years of infection, 526
gender differences in, 666
as lymph node viral load indicator, 850
monitoring, in pediatric patients, 1089
as progression marker, in pediatric patients, 1514
in semen, antiretroviral drug effects on, 2039
temporal trends in, 1018
vs. therapy efficacy, 1851
susceptibility to, *NRAMP1* gene variants in, 1521
Human immunodeficiency virus infection (type 1 or unspecified)
acute (*See subheading* primary [acute])
advanced
cytomegalovirus infections in, 695
neutrophil dysfunction in, 1542
AIDS dementia complex in, *CCR5* genotypes in, 854
anemia in, erythropoietin autoantibodies in, 2044
animal models (*See also* Simian immunodeficiency virus infection)
cat (feline immunodeficiency virus infection), 1503
antibodies in (*See* Human immunodeficiency virus [type 1 or unspecified], antibodies to)
bacteremia in, *Mycobacterium avium,* bone marrow and blood cultures in, 438
bloodstream infections in, emerging pathogen monitoring and, 87
Candida albicans infections in, protease inhibitor effects on, 448
chemokine production in, 858
cognitive impairment in, cerebrospinal fluid chemokine levels and, 310
counseling on, for women, 99
Cryptococcus neoformans infections in

capsular polysaccharide glucuronoxylomannan antibodies in, in pediatric patients, 915
immune activation induced by, 559
meningitis, antibody profiles in, 1526
smoking effects on, 1412
cytomegalovirus infections in
esophageal, 211
highly active antiretroviral therapy effects on, 847
prophylaxis, 571
valacyclovir for, 695
endotoxin responses in, 106
epidemiology
circumcision effects on, 330
in women, North Carolina, 99
esophageal ulcers in
pathogenesis, 211
treatment with thalidomide, 61
GB virus C (hepatitis G virus) infections in, treatment, 1334
genetic evolution in, in injection drug users, 1025
genital ulcers in, treatment, 1886
hepatitis B in, treatment, 607
hepatitis C in
protease inhibitor effects on, 574
treatment, highly active antiretroviral therapy, 2027
herpes simplex virus infections in, treatment failure in, 487
in homosexual population (*See* Homosexual population)
human herpesvirus 6 infections in, in pediatric patients, 50
human herpesvirus 8 cellular immune response in, 1682
human herpesvirus 8 infections in, epidemiology, homosexual men, United States, 1010
vs. human immunodeficiency virus infection type 2, pathogenicity comparison, 1116
human papillomavirus infection in, 1316
immunogen evaluation in
in pediatric patients, 626
phenotypic analysis in, 641
interleukin-2 production in, after highly active antiretroviral therapy, 1057
lymphadenopathy in, interleukin-6 production in, 824
macrophage tropism in, 344
meningitis in, *Cryptococcus neoformans*, antibody profiles in, 1526
microsporidiosis in, 929, 2006
Mycobacterium avium infections in
bone marrow and blood cultures in, 438
treatment, 229
viral replication in, 1142
natural history, 1803 (*See also subheadings* nonprogression *and* progression)
human leukocyte antigens and, 299
stromal-derived factor 1 chemokine polymorphism and, 285
T cell dysfunction and, 278
viral load during, 526
in pediatric patients, 1838
nonprogression
chemokine receptors and, 1106
cytotoxic T cell decline in, macaque model, 1133
in hemophilia cohort, 1790
stromal-derived factor 1 chemokine polymorphism and, 285
vs. viral load, 526, 666
p24 antigen monitoring in, in pediatric patients, 1089
in pediatric patients (*See* Pediatric patients, human immunodeficiency virus infection in)
phagocytosis in, neutrophil damage and, 206
Pneumocystis carinii pneumonia prevention in, 369
in pregnancy (*See also subheading* transmission, perinatal)
didanosine pharmacokinetics in, 1536
vaccination in, 1080
prevention, in neonates, maternal zidovudine for, 1844
primary (acute)
T cell dysfunction in, 278
treatment, 1342, 1827
potent, T cell subsets after, 320
progression
antibody-dependent cellular cytotoxicity prediction, 1338
CD3 T cell reduction and, 649
chemokine receptors and, 1096, 1106
human leukocyte antigens and, 299
markers for, in pediatric patients, 1514
stromal-derived factor 1 chemokine polymorphism and, 285
vs. viral load, 526, 666, 1018
progressive multifocal leukoencephalopathy in
JC virus load in, 1690
survival in, 621
resistance in, to drugs
in injection drug users, 1025
reverse transcriptase sites in, 1043
resistance to, 871, 1406
risk factors for, vaginal microflora and, 1863
seroconversion in
vs. CD4 T cell levels, 1803
treatment before, 1827
viral load temporal trends after, 1018
seronegative, persistently, viral and immunologic examination in, 1033
severe immunodeficiency in, antibody-dependent cellular cytotoxicity studies in, 1338
smoking effects on, 1412
Staphylococcus aureus nasal carriage in, eradication, 896
subtype E, transmission, Thailand, 337
T cells in
in acute stage, 278
antibody effects on, 1072
CD3, destruction, 649
CD4
in antiretroviral therapy efficacy prediction, 530
human leukocyte antigens and, 299
as progression markers, in pediatric patients, 1514
response to antiretroviral therapy, 1050, 1057
vs. viral load, 1018
CD8, anti–human immunodeficiency virus suppressor activity, 68
chemokine receptor polymorphisms and, 1096
cytotoxic
combination antiretroviral agent effects on, 359
in repeated exposure without seroconversion, 1406
early treatment effects on, 320, 1827
granulocyte colony-stimulating factor effects on, 1819
L-selectin–negative, cat model, 1503
in nonprogressive disease, 1790
phosphoantigen-reactive, 858
polyspecific self-reactive antibody effects on, 1072
as progression markers, in pediatric patients, 1514
reconstitution, in highly active antiretroviral therapy, 76
RNA-positive, vs. therapy efficacy, 1851
type 1 vs. type 2, 1116
vs. year of seroconversion, 1803

zoster incidence and, 1784
testing for, in women, 99
toxoplasmosis in, CCR5 deletion and, 920
transmission
in breast milk, 93
chemokine receptor mutations and, 614
circumcision effects on, 330
perinatal
factors affecting, 344
human herpesvirus infections with, 50
mastitis and, 93
maternal vaccination effects on, 1080
trends in, North Carolina, 99
Thailand, 337
vaginal microflora and, 1863
treatment
in advanced disease, 659
antiretroviral agents (*See* Antiretroviral agents; Highly active antiretroviral therapy; *specific agents*)
clinical trials, 351
combination, in pediatric patients, 359
didanosine (*See* Didanosine)
efavirenz, 862
failure, 568, 865
granulocyte colony-stimulating factor, 1819
granulocyte-macrophage colony-stimulating factor, 1064
highly active antiretroviral therapy (*See* Highly active antiretroviral therapy)
hydroxyurea, 1827
immune reconstitution after, 1050
immunogen in
in pediatric patients, 626
phenotypic analysis after, 641
indinavir (*See* Indinavir)
interleukin-1, 56
lamivudine (*See* Lamivudine)
monitoring, in pediatric patients, 1089
potent, T cell subsets after, 320
in pregnancy, didanosine pharmacokinetics in, 1536
primary, 320, 1343, 1827
progressive multifocal leukoencephalopathy survival in, 621
protease inhibitors
α_1-acid glycoprotein concentration, 1833
anticandidal activity, 448
before seroconversion, 1827
vs. T cell populations, 1851
vs. viral load, 1851
in women, 99, 1844
zidovudine (*See* Zidovudine)
trimethoprim-sulfamethoxazole resistance in, 1809
tuberculosis in
immune response in, 2069
transmission, barhopping and, 1245
vaccination
canarypox-based, 290, 1122
in pediatric patients, 626
phenotypic analysis after, 641
in pregnancy, 1080
vasculitis in, 176
viral load in
vs. *Candida* colonization, 534
cell-associated vs. lymph node, 850
during first years, 526
gender differences in, 666
in lymph nodes, blood test for, 850
as progression marker, in pediatric patients, 1514
in semen, antiretroviral drug effects on, 2039
temporal trends in, 1018
vs. therapy efficacy, 1851
vs. type 2, pathogenicity comparison, 1116
in untreated pediatric patients, 1838
viral mutation in, treatment failure in, 568
zoster in, epidemiology, 1784
Human immunodeficiency virus infection (type 2)
susceptibility window for dual isolate infection, macaque model, 673
viral load in, vs. type 1, 1116
viral replication in, BOB/GPR15 orphan receptor in, 1494
Human leukocyte antigens
associations with *Chlamydia trachomatis* heat-shock protein 60, 234
human immunodeficiency virus progression and, 299
Human papillomavirus
infections, epidemiology, cervical cancer and, Brazil, 1415
seroreactivity to, in cervical squamous intraepithelial lesions, 1424
vaginal, hybrid capture assay for, 1316
Human T cell lymphotropic virus type I
infections
epidemiology, United States, 1777
screening for, in neurologic disease, 685
natural history, proviral DNA levels in, 1487
uveitis, susceptibility to, tumor necrosis factor gene polymorphism and, 880
Human T cell lymphotropic virus type II, infections
epidemiology, United States, 1777
risk factors for, Panama, 876
Humoral immune response (*See also* Antibody[ies])
to *Cryptococcus neoformans*
in human immunodeficiency virus infection, 1526
mouse model, 791
to cytomegalovirus glycoprotein B subunit vaccine, 1700
to human immunodeficiency virus, 871
to malaria vaccine, mechanisms, 1656
to neisserial porins, mouse model, 755
to pneumococcal vaccination, 1569
to respiratory syncytial virus
monoclonal antibody, mouse model, 708
with pertussis vaccination, mouse model, 714
to *Schistosoma mansoni*, familial resemblance in, 1665
Hybrid capture assay, for human papillomavirus in vaginal swabs, 1316
Hydroxyurea, for human immunodeficiency virus infection, before seroconversion, 1827
Hyperimmune milk product, bovine, for enterotoxigenic *Escherichia coli* diarrhea prevention, 2056
Hypertension, portal, in schistosomiasis, 1298

Immune response (*See also* Cellular immune response; Humoral immune response)
to antiretroviral therapy, in human immunodeficiency virus infection, 1050, 1057
in *Borrelia crocidurae* infections, mouse model, 1929
to *Chlamydia trachomatis*, doxycycline effects on, mouse model, 1252
heterosubtypic, T cell expansion in, mouse model, 579
to human immunodeficiency virus, dysfunction in, 1033

in Kawasaki disease, 1869
to *Listeria monocytogenes*, amphotericin B suppression, mouse model, 1186
to *Trypanosoma cruzi trans*-sialidase, 1398
Immunization (*See* Vaccination)
Immunodeficiency (*See also* Human immunodeficiency virus infection [type 1 or unspecified])
in agammaglobulinemia, ganciclovir-resistant cytomegalovirus infections in, in pediatric patients, 491
Aspergillus fumigatus pulmonary infections in, interleukin-4 and, mouse model, 1957
human granulocytic ehrlichiosis in, mouse model, 546
Immunogen, for human immunodeficiency virus infection
in pediatric patients, 626
phenotypic analysis after, 641
Immunoglobulin(s)
bovine, for enterotoxigenic *Escherichia coli* diarrhea prevention, 2056
in *Cryptococcus neoformans* meningitis, in human immunodeficiency virus infection, 1526
formation, in human immunodeficiency virus exposure, 871
human immunodeficiency virus, polyspecific self-reactive, in T cell deletion, 1072
in respiratory syncytial virus protection, mouse model, 1324
in schistosomiasis susceptibility, 1665
Indinavir, for human immunodeficiency virus infection, 76
α_1-acid glycoprotein concentration effects on, 1833
advanced, 659
anticandidal activity, 448
$CD8^+$ anti–human immunodeficiency virus suppressor activity, 68
granulocyte-macrophage colony-stimulating factor with, 1064
hepatitis C viremia and, 574
before seroconversion, 1827
Infants (*See* Neonatal infections; Pediatric patients)
Inflammation
prolonged, in pneumococcal infections, in elderly persons, 551
in tuberculous pleurisy, transmesothelial monocyte migration in, 1616
Influenza virus
avian, 505, 1763
infections
experimental, cytokine modification of, 10
treatment, zanamivir, 254, 586
in interferon-τ production enhancement, 1477
resistance in, rimantadine, 935
vaccination
age factors in, 1356
immunoglobulin subclass responses in, 1356
inactivated, T helper cell response to, mouse model, 579
nasal, mouse model, 940
Integrins, receptors for, on *Candida albicans*, 156
Intercellular adhesion molecule–1
in tuberculosis resistance, 141
in tuberculous pleurisy pathophysiology, 1616
Interferon(s)
deficiency, in hepatitis C, 262
hepatitis C virus mutations and, 1001
Interferon-α
for GB virus C (hepatitis G virus) infections, in human immunodeficiency virus infection, 1334
for hepatitis C virus infections, 1411
production, in chronic hepatitis B, vaccine therapy effects on, 15
Interferon-τ
in chronic hepatitis B, vaccine therapy effects on, 15
in *Cryptococcus neoformans* infection defense, mouse model, 1637
in *Escherichia coli* kidney infections, mouse model, 1374
in influenza
interleukin-12 enhancement, 1477
zanamivir effects on, 586
in leishmaniasis, cutaneous, 1731
Listeria monocytogenes intracellular growth effects on, 1195
in malaria
pathogenesis and prognosis, 1288
vaccine response, 1656
in melioidosis, 1878
in mucosal *Haemophilus influenzae* immunization, mouse model, 122
in tuberculosis, 2069
for visceral leishmaniasis, mouse model, 811
in *Yersinia pseudotuberculosis* mitogen stimulation, mouse model, 1590
Interleukin(s)
in *Cryptococcus neoformans* infection defense, mouse model, 1637
deficiency, in hepatitis C, 262
in influenza, zanamivir effects on, 586
in leishmaniasis, cutaneous, 1731
in malaria
anemia, 1753
in pregnancy, intrauterine growth retardation in, 1987
in melioidosis, 1878
in pneumococcal infections, in elderly persons, 551
response
to lipopolysaccharide, in human immunodeficiency virus infection, 106
to mucosal *Haemophilus influenzae* immunization, mouse model, 122
in sepsis, 908
in *Staphylococcus aureus* osteomyelitis, mouse model, 1912
Interleukin-1
in *Candida albicans* infections, Fas-FasL interactions in, mouse model, 1648
low-dose subcutaneous, for human immunodeficiency virus infection, 56
Interleukin-1 receptor antagonist
amphotericin B and, 1408
gene polymorphism, vaginal colonization and, 912
in pneumococcal infections, in elderly persons, 551
in sepsis, 908
Interleukin-1α, in streptococci group A defense, 1718
Interleukin-1β
amphotericin B and, 1408
intrahepatic, in hepatitis C, 1704
in monocytes, amphotericin B–induced, 1259
in Shiga toxin interactions with brain endothelial cells, 1205
Interleukin-2, in human immunodeficiency virus infection, after highly active antiretroviral therapy, 1057
Interleukin-4
in pertussis vaccination, mouse model, 714
in pulmonary aspergillosis susceptibility, mouse model, 1957
Interleukin-6
Aspergillus fumigatus protease induction, 1267
in human herpesvirus 6 infections, 824
in influenza mediation, 10
Listeria monocytogenes intracellular growth effects, 1195
in malaria pathogenesis and prognosis, 1288
urinary, in neonatal urinary tract infections, 904

Interleukin-8
Aspergillus fumigatus protease induction, 1267
in *Cryptococcus neoformans* response, in human immunodeficiency virus infection, 1542
as cytomegalovirus infection indicator, in kidney transplantation, 195
in influenza mediation, 10
urinary, in neonatal urinary tract infections, 904
Interleukin-10
gene polymorphism, Epstein-Barr virus susceptibility and, 496
in malaria pathogenesis and prognosis, 1288
in *Mycobacterium avium* infections, 1230
in tuberculosis, 2069
Interleukin-12, as viral vaccine adjuvant, mouse model, 940
Iron
in cryptococcosis, smoking and, 1412
in hepatitis C pathogenesis, 1412
Ivermectin, for *Mansonella streptocerca,* 1403

JC virus
in cerebrospinal fluid, in progressive multifocal leukoencephalopathy, in human immunodeficiency virus infection, 1690
infections, in systemic lupus erythematosus, 1

Kala-azar, drug resistance in, 564
Kaposi's sarcoma (*See also* Human herpesvirus 8)
epidemiology, homosexual men, United States, 1010
human herpesvirus 8 cellular immune response and, 1682
human herpesvirus 8 transmission and, 600
interleukin-6 production in, 824
Kawasaki disease, immune response defects in, 1869
Keratinocytes, streptococci group A adherence to, host defenses in, 1718
Kidney
Escherichia coli effects on, mouse model, 1374
hemolytic uremic syndrome
endothelial cell apoptosis in, 2048
in infections, 176
pulmonary epithelium–derived cell apoptosis in, 1902
infections
interleukin-6 production in, in neonates, 904
resistance to, neutrophil recruitment in, mouse model, 1220
pathology, in *Borrelia crocidurae* infections, mouse model, 1929
transplantation
cytomegalovirus infections in, predictive markers for, 195
hepatitis A virus vaccination in, 2014
T cell response to cytomegalovirus, 247
Klebsiella
resistance in, trimethoprim-sulfamethoxazole, 1809
sepsis, vs. tumor necrosis factor–α levels, 116

Lactobacillus, vaginal
vs. behavior, 1632
colonization, species identification, population demographics and, 1950
human immunodeficiency virus infection transmission risk and, 1863
nonoxynol-9 preparation effects on, 426
Lamivudine
for hepatitis B, viral variants, 1757
for human immunodeficiency virus infection
advanced, 659
clinical trials, 351
with hepatitis B coinfection, 607
hepatitis C viremia and, 574
resistance in, 865
viral semen loads and, 2039
Leishmania braziliensis, infections
T cell response in, 1731
treatment, 1735
Leishmania donovani, resistance in, antimony compounds, 564
Leishmaniasis
cutaneous
T cell response in, 1731
treatment, 1735
visceral, treatment, doxorubicin and interferon-τ for, mouse model, 811
Leptin, production, in sepsis, 908
Leptospirosis, coagulation disorders in, 176
Leukemia, adult T cell, natural history, proviral DNA levels in, 1487
Leukoencephalopathy, progressive multifocal, in human immunodeficiency virus infection, 621
JC virus load in, 1690
Lipo-oligosaccharide, *Neisseria meningitidis,* in vaccination, mouse model, 747
Lipopolysaccharide (endotoxin)
in human immunodeficiency virus infection, 106
in sepsis, vs. lipopolysaccharide-binding protein levels, 1584
in Shiga toxin interactions with brain endothelial cells, 1205
Lipopolysaccharide-binding protein, in sepsis, vs. lipopolysaccharide levels, 1584
Lipoprotein, low-density, oxidized
adhesion to CD36 receptor, 473
Chlamydia pneumoniae in, 780
Liposome formulations, doxorubicin, for visceral leishmaniasis, mouse model, 811
Listeria monocytogenes
acquired immunity to, amphotericin B suppression, mouse model, 1186
intracellular growth, cytokine effects on, 1195
Liver
cirrhosis
in hepatitis C, pathogenesis, 1412
spontaneous bacterial peritonitis in, treatment, 1597
TT viremia in, 838
cytokines within, in hepatitis C, 1704
cytomegalovirus infections, cells targeted in, 976
inflammation (*See* Hepatitis [A–G] virus)
periportal fibrosis, in schistosomiasis, 1298
transplantation, hepatitis A virus vaccination in, 2014
Lung
epithelium-derived cells, *Escherichia coli* Shiga toxin effects on, 1902
infections (*See also* Pneumonia)
Aspergillus fumigatus, interleukin-4 and, mouse model, 1957
pathology, in *Borrelia crocidurae* infections, mouse model, 1929
Lung surfactant proteins, binding to respiratory syncytial virus fusion glycoprotein, 2009
Lyme disease
encephalopathy in, treatment with ceftriaxone, 377
hematogenous dissemination, organism subtypes associated with, 720
Lymph nodes, human immunodeficiency virus load in, blood test for, 850
Lymphadenopathy, human immunodeficiency virus–associated, interleukin-6 production in, 824

Lymphocyte function antigen-1, in tuberculosis resistance, 141
Lymphocytes (*See also* T cells)
  thalidomide effects on, 216
Lymphogranuloma venereum, testing for, in genital ulcer disease, 1382
Lymphoma
  adult T cell, natural history, proviral DNA levels in, 1487
  human herpesvirus 6–associated, interleukin-6 production in, 824
  human herpesvirus 8–associated, epidemiology, 1466
Lymphoproliferative response, to HIV antigens, in highly active antiretroviral therapy, 76
Lymphotoxin-α, in *Cryptococcus neoformans* infection defense, mouse model, 1637

Macrophage(s)
  activity, in hepatitis C, 1412
  apoptosis, *Mycobacterium avium* in, interleukin-10 effects on, 1230
  human immunodeficiency virus tropism for, mother-to-infant transmission and, 344
  natural resistance–associated macrophage protein 1, mutations, human immunodeficiency virus infection susceptibility and, 1521
Macrophage inflammatory proteins
  in cerebrospinal fluid, in human immunodeficiency virus infection, 310
  as cytomegalovirus infection indicators, in kidney transplantation, 195
  in influenza, zanamivir effects on, 586
  in pneumococcal infections, in elderly persons, 551
Major histocompatibility complex, in tuberculosis resistance, 141
Malaria
  anemia in, cytokine balance in, 1753
  cerebral
    cytokine expression in, 1742
    pathogenesis, cytokines in, 1288
    resistance in, chloroquine, epidemiology, Saudi Arabia, 1738
  epidemiology, genetic characterization, Yanomami Amerindians, 2081
  hemoglobin levels in, thalassemia and microcytosis effects on, 925
  nitric oxide synthase promoter polymorphisms in, 1994
  in pregnancy
    intrauterine growth retardation in, 1987
    pathogenesis, 464
  resistance in, chloroquine, 1738, 1979
  severe, pathogenesis, cytokines in, 1288
  treatment
    mefloquine, 2077
    tafenoquine, 1282
  vaccination, immune effector mechanisms in, 1656
Mannose-binding proteins, binding to respiratory syncytial virus fusion glycoprotein, 2009
Mansonella streptocerca, infections, ivermectin for, 1403
Mastitis, human immunodeficiency virus transmission and, 93
Matrix metalloproteinases, *Mycobacterium avium,* in human immunodeficiency virus replication modulation, 1142
Measles virus
  vaccination, dose intervals in, 187
  virulence of strains, macaque model, 950
MEDI-493 respiratory syncytial virus monoclonal antibody, activity, 35
Mefloquine, for malaria, 2077
Melioidosis, cytokine levels in, 1878
Meningitis
  Cryptococcus neoformans, in human immunodeficiency virus infection, antibody profiles in, 1526
  Neisseria meningitidis, epidemiology, United States, 1894
  Streptococcus pneumoniae, pathophysiology, rat model, 1164
  treatment with rolipram, rat model, 1550
Meningococci
  infections, epidemiology, United States, 1894
  vaccination
    efficacy, 242
    mouse model, 747
Meningoencephalitis, *Borrelia crocidurae,* mouse model, 1929
Mesothelium, monocyte migration across, in pleural tuberculosis, 1616
Metalloproteinases, *Mycobacterium avium,* in human immunodeficiency virus replication modulation, 1142
Metronidazole, in vancomycin-resistance promotion, 384
MF59 adjuvant, in cytomegalovirus vaccine, 970
Microcytosis, in malaria, hemoglobin levels in, 925
Microfilariasis, *Mansonella streptocerca,* ivermectin for, 1403
Microsporidiosis
  in dogs and humans, 2086
  in human immunodeficiency virus infection, 929, 2006
Milk, breast, human immunodeficiency virus transmission in, 93
Mitogen, *Yersinia pseudotuberculosis,* colonic epithelial pathophysiology and, mouse model, 1590
Monoclonal antibodies
  for *Cryptococcus neoformans* infections, mouse model, 791
  Epstein-Barr virus, in respiratory syncytial virus neutralization, mouse model, 268
  respiratory syncytial virus
    activity, 35
    mouse model, 708, 1324
Monocyte(s)
  interleukin-1β production in, amphotericin B–induced, 1259
  in *Mycobacterium avium* killing, in human immunodeficiency virus infection, 229
  thalidomide effects on, 216
  transmesothelial migration, in pleural tuberculosis, 1616
  in tuberculosis resistance, 141
Monocyte chemoattractant proteins, in *Cryptococcus neoformans* infection defense, mouse model, 1637
  in influenza, zanamivir effects on, 586
Morganella, resistance in, trimethoprim-sulfamethoxazole, 1809
Mortality
  in malaria, cytokines in, 1288
  in melioidosis, cytokines in, 1878
  in meningococcal disease, 1894
Multiorgan failure, in coagulation disorders, in infections, 176
Mumps virus
  genotypes, in United Kingdom, 829
  neurovirulence safety test, monkey model, 521
  vaccination, neurovirulence safety test for, monkey model, 521
Mupirocin, in *Staphylococcus aureus* nasal carriage eradication, in human immunodeficiency virus infection, 896
Mutations (*See also* Polymorphisms)
  cg2 gene, *Plasmodium falciparum,* 1979
  chemokine receptors (*See* Chemokines and chemokine receptors)
  drug resistance due to (*See* Drug resistance)
  hepatitis B virus, naturally occurring, 1444
  hepatitis C virus, interferon effects on, 1001
  human immunodeficiency virus
    in injection drug users, 1025
    treatment failure in, 568
  interleukin-10 gene, Epstein-Barr virus susceptibility and, 496

nitric oxide synthase type 2 promoter, in malaria, in pediatric patients, 1994
NRAMP1 gene, human immunodeficiency virus infection susceptibility and, 1521
Pneumocystis carinii dihydropteroate synthase gene, 1969
reverse transcriptase, human immunodeficiency virus, 1043
tumor necrosis factor–α gene, human T cell lymphotropic virus type I uveitis susceptibility and, 880
MxA protein, induction in hepatitis C, 262
Mycobacterium, bacteremia, emerging pathogen monitoring and, 87
Mycobacterium avium, infections
in human immunodeficiency virus infections
replication modulation, 1142
bone marrow and blood cultures in, 438
pathogenesis, 1230
treatment, 229
Mycobacterium tuberculosis (*See also* Tuberculosis)
bacteremia, emerging pathogen monitoring and, 87
resistance in
mutations in, 1751
transmission, 1608
resistance to, phenotypically activated $\gamma\delta$ T cells in, 141
restriction fragment length polymorphism patterns, serial rate of change, 1238
Mycoplasma hominis, vaginal colonization, interleukin-1 receptor antagonist gene polymorphism and, 912

Naphthalene sulfonate polymer PRO2000, in genital herpes prevention, mouse model, 199
Natural killer cells
activity evaluation, in severe immunodeficiency, in human immunodeficiency virus infection, 1338
in dengue hemorrhagic fever, in pediatric patients, 1429
in tuberculosis resistance, 141
Natural resistance–associated macrophage protein 1, mutations, human immunodeficiency virus infection susceptibility and, 1521
Neisseria gonorrhoeae, infections
epidemiology, urban adolescent females, 1624
T cell response to, 762
transmission, vaginal microflora and, 1863
Neisseria meningitidis
infections, epidemiology, United States, 1894
vaccination
efficacy, 242
mouse model, 747
Neisserial porins, immune response to, 762
mouse model, 755
Nelfinavir, for human immunodeficiency virus infection
α_1-acid glycoprotein concentration effects on, 1833
resistance in, 865
Neonatal infections
cytomegalovirus, prenatal diagnosis, 1320
herpes simplex virus, epidemiology, California, 199
human herpesvirus 6, 2035
human immunodeficiency virus infection (*See also* Human immunodeficiency virus infection [type 1 or unspecified], transmission, perinatal)
didanosine pharmacokinetics in, 1536
zidovudine for, 1844
streptococci, group B, vaccination for, rabbit model, 892
urinary, interleukin-6 levels in, 904
Neuroborreliosis, treatment with ceftriaxone, 377
Neurocysticercosis, serologic testing for, 1307
Neuroendocrine response, to lipopolysaccharide, in human immunodeficiency virus infection, 106
Neurologic disorders, human T cell lymphotropic virus type I infections, 685
Neuropsychiatric disorders, Borna disease virus in, 1695
Neurovirulence safety test, for mumps virus, monkey model, 521
Neutralizing antibodies
cytomegalovirus, in bone marrow transplantation, 1747
human immunodeficiency virus, 871
lack of, human immunodeficiency virus infection transmission and, 344
streptococcal, toxic shock syndrome risk and, 410
Neutrophil(s)
in *Candida albicans* infections, Fas-FasL interactions in, mouse model, 1648
chemotaxis, on catheter surfaces, 1603
in human immunodeficiency virus infection, 206, 1542
in *Mycobacterium avium* killing, in human immunodeficiency virus infection, 229
in pneumococcal infections, in elderly persons, 551
recruitment, in urinary tract infections, mouse model, 1220
YKL-40 protein, in pneumonia, 1722
Neutrophil A_{1A} adenosine receptor, synergy with rolipram, in meningitis, rat model, 1550
Nevirapine, for human immunodeficiency virus infection, resistance to, 1043
Nitric oxide
Helicobacter pylori morphologic effects, 1713
production
in gastroenteritis, 542
in malaria, in pediatric patients, 1994
Nitric oxide synthase
production
cytokine stimulation, *Listeria monocytogenes* intracellular growth and, 1195
type 2 promoter, in malaria, in pediatric patients, 1994
Nitrite/nitrate, in *Cryptococcus neoformans* infection defense, mouse model, 1637
Nonoxynol-9 preparations, vaginal flora and epithelial effects of, 426
Norepinephrine, response to lipopolysaccharide, in human immunodeficiency virus infection, 106
Norwalk-like viruses, gastroenteritis, from drinking water, 1771
Nose
immunization in
Haemophilus influenzae, mouse model, 122
viral, interleukin-12 adjuvant for, mouse model, 940
immunoglobulin administration in, in respiratory syncytial virus protection, 1324
pneumococcal carriage, after vaccination, 1171
Staphylococcus aureus carriage, in human immunodeficiency virus infection, eradication, 896
Nosocomial infections
enterococci, vancomycin-resistant, from interfacility patient transfer, 391
GB virus C, in hemodialysis, 191
respiratory syncytial virus, molecular characterization, 1686
NRAMP1 gene, mutations, human immunodeficiency virus infection susceptibility and, 1521

2′,5′-Oligoadenylate synthetase, deficiency, in hepatitis C, 262
Onchocerca volvulus, treatment, dermatitis after, eotaxin expression in, 1394
O'nyong-nyong fever, epidemiology, Uganda, 1436
Opsonophagocytosis

Streptococcus pneumoniae, mouse model, 133
variable susceptibility to, streptococcus group A M-1 strain, 1921
Oral cavity, *Candida* colonization, in human immunodeficiency virus infection, vs. viral load, 534
Osteoblasts, interleukin production in, in *Staphylococcus aureus* osteomyelitis, mouse model, 1912
Osteomyelitis, *Staphylococcus aureus*, pathogenesis, mouse model, 1912
Outbreaks
respiratory syncytial virus infections, nosocomial, molecular characterization, 1686
Salmonella enterica enteritis, Wisconsin, 1214
Salmonella saphra, from Mexican cantaloupes, 1361

p24 antigen, human immunodeficiency virus, monitoring, in pediatric patients, 1089
par genes, in fluoroquinolone resistance transfer, 555
Paraparesis, tropical spastic, natural history, proviral DNA levels in, 1487
Parvovirus B19, infections, antibodies after, nonstructural protein type, vs. clinical outcome, 500
Passive immunotherapy, for respiratory syncytial virus infections, mouse model, 268
Pediatric patients (*See also* Neonatal infections)
astrovirus infections in, epidemiology, in child care centers, 514
Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan antibodies in, 915
Cryptosporidium infections in, epidemiology, Brazil, 167
dengue hemorrhagic fever in, CD69 expression in, 1429
Helicobacter pylori infections in, paternal and maternal infection status and, 1407
hepatitis A in, epidemiology, South Texas, 509
human herpesvirus 6 infections in, 50
human immunodeficiency virus infection in
Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan antibodies in, 915
didanosine pharmacokinetics in, 1536
epidemiology, North Carolina, 99
human herpesvirus 6 infections with, 50
immunogen evaluation in, 626
p24 antigen monitoring in, 1089
progression, markers for, 1514
transmission to
in breast milk, 93
epidemiology, North Carolina, 99
factors affecting, 344
human herpesvirus infections with, 50
prevention, 99
treatment, combination, 359
viral load in, without treatment, 1838
immunodeficiency in, ganciclovir-resistant cytomegalovirus infections in, 491
influenza vaccination in, immunoglobulin subclass responses in, 1356
malaria in
hemoglobin levels in, thalassemia and microcytosis effects on, 925
nitric oxide synthase promoter polymorphisms in, 1994
pathogenesis, 464
pneumococcal vaccination in, crossreactivity in, 1569
respiratory syncytial virus infections in, epidemiology, Alaskan native children, 41
simian virus 40 infections in, 884
Pefloxacin, resistance to, streptococci, 555
Peliosis, human herpesvirus 8 absent from, 1386
Pelvic inflammatory disease, *Chlamydia trachomatis*
genetic factors in, 234
heat-shock protein 60 antibody in, monkey model, 774
Penicillium marneffei, fungemia, emerging pathogen monitoring and, 87
Pentamidine, aerosolized, for *Pneumocystis carinii* pneumonia prevention, in human immunodeficiency virus infection, 369
Peptic ulcer disease, *Helicobacter pylori*, in couples, 2064
Peritonitis, spontaneous bacterial, treatment, cephalosporins, 1597
Peroxynitrite, in pneumococcal meningitis pathophysiology, rat model, 1164
Pertussis, vaccination (*See also* Diphtheria-tetanus-pertussis vaccination)
acellular, in adults, 397
respiratory syncytial virus response in, mouse model, 714
Phagocytosis
Candida albicans, Fas-FasL interactions in, mouse model, 1648
in human immunodeficiency virus infection, neutrophil damage and, 206
Mycobacterium avium, in human immunodeficiency virus infection, 229
Streptococcus pneumoniae
mediated by pneumococcal conjugate sera, 888
mouse model, 133
variable susceptibility to, streptococcus group A M-1 strain, 1921
Pharynx, *Candida* colonization, in human immunodeficiency virus infection, vs. viral load, 534
Phosphoantigens, T cells responsive to, in human immunodeficiency virus suppression, 858
Phosphodiesterase inhibitors, for meningitis, rat model, 1550
Piperacillin-tazobactam, in vancomycin-resistance promotion, 384
Placenta, *Plasmodium falciparum* in, intrauterine growth retardation and, 1987
Plasmodium falciparum
in erythrocytes, adhesion to CD36 receptor, 473
infections
anemia in, cytokine balance in, 1753
cytokine expression in, 1742
epidemiology, genetic characterization, Yanomami Amerindians, 2081
in microcytosis, hemoglobin levels in, 925
pathogenesis, cytokines in, 1288
in pregnancy
intrauterine growth retardation in, 1987
pathogenesis, 464
in thalassemia, hemoglobin levels in, 925
treatment, mefloquine, 2077
vaccination, immune effector mechanisms in, 1656
resistance in, chloroquine, 1738, 1979
Plasmodium vivax, infections, treatment, 1282
Pleural space, tuberculosis, transmesothelial monocyte migration in, 1616
Pneumococcal surface protein serotyping, in multidrug-resistant pneumococci characterization, 1577
Pneumococci (*Streptococcus pneumoniae*)
bacteremia
emerging pathogen monitoring and, 87
mouse model, 133
infections, prolonged inflammation in, in elderly persons, 551
meningitis, pathophysiology, rat model, 1164
phagocytosis, mediated by pneumococcal conjugate sera, 888

pneumonia, YKL-40 protein levels in, 1722
resistance in
study methods for, 1577
transfer, 555
sepsis, vs. tumor necrosis factor–α levels, 116
vaccination
crossreactivity in, 1569
mouse model, 133
nonavalent conjugate, 1171
Pneumocystis carinii
pneumonia, in human immunodeficiency virus infection, prevention, 369
resistance in, 1969
Pneumonia
avian influenza virus, risk factors for, 505
neutrophil YKL-40 protein levels in, 1722
Pneumocystis carinii, in human immunodeficiency virus infection, prevention, 369
pol gene, human immunodeficiency virus, mutations, in injection drug users, 1025
Polyarthralgia, in o'nyong-nyong fever, 1436
Polymerase chain reaction
amplification refractory mutation system, for chemokine receptors, 1096
for *Bartonella*, in rat reservoirs, 220
for *Borrelia burgdorferi* subtypes, 720
for *Chlamydia pneumoniae*, 2074
for cytomegalovirus, 491
for cytomegalovirus antigens, 247
for enterotoxigenic *Escherichia coli*, 2053
for hepatitis B virus, 1757
for hepatitis C virus, 2027
for human immunodeficiency virus, p24 antigen, 1089
for human papillomavirus, 1415
for JC virus, 1690
reverse transcriptase nested, for mumps virus, 829
reverse transcription
for astrovirus, 514
for cytokines, in cerebral malaria, 1742
for hantavirus, 2030
for human immunodeficiency virus, 862
type 2, 1116
for Norwalk-like virus, 1771
for Sin Nombre virus, 2030
for simian virus 40, 884
for *Trypanosoma cruzi*, 480
for TT virus, 27, 838, 1748, 1750
for vancomycin-resistant *Enterococcus faecium*, 1177
Polymerase gene, hepatitis B virus, mutations, 1444
Polymorphisms (*See also* Mutations)
chemokines and chemokine receptors (*See* Chemokines and chemokine receptors)
Fc$_\gamma$ receptor, pneumococcal phagocytosis and, 888
interleukin-10 gene, Epstein-Barr virus infection susceptibility and, 496
interleukin-1 receptor antagonist gene, in bacterial vaginosis, 912
latent nuclear antigens, human herpesvirus 8, 1466
nitric oxide synthase promoter, in malaria, 1994
Plasmodium falciparum cg2 gene, 1979
tumor necrosis factor gene, human T cell lymphotropic virus type I uveitis susceptibility and, 880
Polyomaviruses, infections, in systemic lupus erythematosus, 1
Polyurethane, neutrophil chemotaxis on, 1603
Porins, neisserial, immune response to, 762
mouse model, 755
Pork tapeworm, brain involvement from, serologic testing for, 1307
Portal hypertension, in schistosomiasis, 1298
Praziquantel, for schistosomiasis, mouse model, 454
Pregnancy
cytomegalovirus infections in, diagnosis, 1320
herpes simplex virus infections in, transmission, 199
human herpesvirus 6 reactivation during, 2035
human immunodeficiency virus infection in (*See also* Human immunodeficiency virus infection [type 1 or unspecified], transmission, perinatal)
didanosine pharmacokinetics in, 1536
vaccination in, 1080
zidovudine pharmacokinetics in, 1844
malaria in
intrauterine growth retardation in, 1987
pathogenesis, 464
Prenatal diagnosis, cytomegalovirus, 1320
Prison, syphilis epidemiology in, women in New York, 1159
PRO2000 (naphthalene sulfonate polymer), in genital herpes prevention, mouse model, 199
Progenitor cells, granulocyte colony-stimulating factor effects on, in human immunodeficiency virus infection, 1819
Progressive multifocal leukoencephalopathy, in human immunodeficiency virus infection
JC virus load in, 1690
survival in, 621
Prophylaxis
cytomegalovirus infections, in human immunodeficiency virus infection, 571
Pneumocystis carinii pneumonia, in human immunodeficiency virus infection, 369
respiratory syncytial virus infections, mouse model, 708
Staphylococcus aureus endocarditis, thrombin-induced platelet microbicidal protein-1 in, rabbit model, 1561
varicella-zoster virus infections, cellular immunity after, 834
Prostatitis, *Escherichia coli*, virulence characteristics, 1378
Protease(s)
Aspergillus fumigatus, in interleukin induction, 1267
canarypox, in human immunodeficiency virus vaccine, 1122
Protease inhibitors, for human immunodeficiency virus infection
anticandidal activity, 448
hepatitis C viremia and, 574
Protein C, deficiency, in infections, 176
Protein D, *Haemophilus influenzae*, epithelial injury, 737
Protein kinase C, thalidomide effects on, 216
Protein S, deficiency, in infections, 176
Proteus, resistance in, trimethoprim-sulfamethoxazole, 1809
Pseudomonas aeruginosa, sepsis, vs. tumor necrosis factor–α levels, 116
Psoriasis, TT viremia in, 838
Psychiatric disorders, Borna disease virus in, 1695
Pulsed-field gel electrophoresis, for multiresistant pneumococci characterization, 1577
Pyelonephritis (*See* Kidney, infections)

Quantitative trait loci, on chromosomes 2 and 9, in tuberculosis resistance, mouse model, 150

Radionuclide studies, in urinary tract infections, in neonates, 904
RANTES (*See* Regulated on activation, normal T cell expressed and secreted)

Rats, as *Bartonella* reservoirs, 220
Regulated on activation, normal T cell expressed and secreted
in cerebrospinal fluid, in human immunodeficiency virus infection, 310
in influenza, zanamivir effects on, 586
Relapsing fever, *Borrelia crocidurae,* erythrocyte aggregation in, mouse model, 1929
Resistance
to drugs (*See* Drug resistance)
to human immunodeficiency virus, 871, 1406, 1521
to tuberculosis, phenotypically activated $\tau\delta$ T cells in, 141
to urinary tract infections, mouse model, 1220
Respiratory infections (*See also* Pneumonia; Tuberculosis)
Aspergillus fumigatus, interleukin-4 and, mouse model, 1957
Haemophilus influenzae, pathogenesis, 737
hantavirus, viral load in, 2030
sepsis in, vs. tumor necrosis factor–α levels, 116
Respiratory syncytial virus
antibodies to, in pertussis vaccination, mouse model, 714
fusion glycoprotein, surfactant protein A binding to, 2009
infections
epidemiology, Alaskan native children, 41
nosocomial, epidemiology, molecular characterization, 1686
protection with passive monoclonal antibodies, mouse model, 1324
treatment
monoclonal antibodies in, 35, 708
passive immunotherapy in, mouse model, 268
neutralization, Epstein-Barr virus antibodies in, mouse model, 268
Restriction analysis, cytomegalovirus, 491
Restriction fragment length polymorphism analysis
for *Borrelia burgdorferi* subtypes, 720
for *Mycobacterium tuberculosis,* 726
multidrug-resistant, 1608
serial rate of change, 1238
for *Plasmodium falciparum,* 2086
for streptococci, toxic shock syndrome risk and, 410
Reverse transcriptase, human immunodeficiency virus, mutations, 1043
Rheumatoid arthritis, TT viremia in, 838
Rickettsial infections, epidemiology, North Carolina, 900
Rimantadine
for influenza, cytokines and, 10
resistance to, influenza virus, 935
Ritonavir, for human immunodeficiency virus infection, 76
α_1-acid glycoprotein concentration effects on, 1833
anticandidal activity, 448
granulocyte-macrophage colony-stimulating factor with, 1064
Rolipram, for meningitis, rat model, 1550
RSHZ19 monoclonal antibody, respiratory syncytial virus
activity, 35
mouse model, 708

S100 β protein, in scrapie, hamster model, 518
Salmonella, bacteremia, emerging pathogen monitoring and, 87
Salmonella enterica, enteritis, epidemiology, Wisconsin, 1214
Salmonella saphra, infections, outbreaks, from Mexican cantaloupes, 1361
Salmonella typhi, infections, vaccination, in epidemics, 2089
Saphenous vein, endothelial cells, Shiga toxin interactions with, 2048
Saquinavir, for human immunodeficiency virus infection, α_1-acid glycoprotein concentration effects on, 1833
Sarcoma, Kaposi's (*See* Kaposi's sarcoma)
Sargramostim, for human immunodeficiency virus infection, 1064
Schistosomiasis
humoral immune response in, familial resemblance in, 1665
periportal fibrosis susceptibility in, 1298
treatment, mouse model, 454
Scrapie, S100 β protein levels in, hamster model, 518
Selectins, in tuberculosis resistance, 141
Semen, human immunodeficiency virus in, antiretroviral drug effects on, 2039
Sepsis and septic shock
Burkholderia pseudomallei, cytokine levels in, 1878
cytokine production in, 908
leptin production in, 908
lipopolysaccharide and lipopolysaccharide-binding protein levels in, 1584
microbiology, 116
Neisseria meningitidis, vaccination, mouse model, 747
severe, microbiology, 116
Staphylococcus aureus, vaccination, mouse model, 1370
Sequestration, *Plasmodium falciparum,* in pregnancy, 464
Serratia, resistance in, trimethoprim-sulfamethoxazole, 1809
Sexual behavior, vs. bacterial vaginosis microbiology, 1632
Sexually transmitted diseases *(See also specific diseases)*
epidemiology, risk behaviors and, urban adolescent females, 1624
human herpesvirus 8 infection, 600
human immunodeficiency virus infection transmission and, 337
human T cell lymphotropic virus type II, 876
transmission
circumcision effects on, 330
vaginal microflora and, 1863
ulcers, 1382, 1886
Shiga toxins
brain endothelial cell interactions with, 1205
Escherichia coli, action on pulmonary epithelium–derived cells, 1902
Shingles, epidemiology, in human immunodeficiency virus infection, 1784
Shock, septic (*See* Sepsis and septic shock)
Sialidase, *Trypanosoma cruzi,* apoptosis induction, mouse model, 1398
Silicone, neutrophil chemotaxis on, 1603
Simian immunodeficiency virus infection
nonprogressive, cytotoxic T cell decline in, macaque model, 1133
viral replication in, BOB/GPR15 orphan receptor in, macaque model, 1494
Simian virus 40, infections, in children, 884
Sin Nombre virus, infections, viral load in, 2030
Single-strand conformation polymorphism analysis, hepatitis C virus, 992
Skin
decontamination, in *Bacillus* exposure, antimicrobial nanoemulsions for, mouse model, 1939
leishmaniasis
T cell response in, 1731
treatment, 1735
streptococci group A host defense in, 1718
SLE (*See* Systemic lupus erythematosus)
Small intestine
bacterial overgrowth in, cholera vaccine immunogenicity and, 1709
biopsy, in microsporidiosis, in human immunodeficiency virus infection, 929
Smith, David Hamilton, tribute to, 577
Smoking, cryptococcosis and, iron role in, 1412
Sodium antimony gluconate, resistance to, *Leishmania donovani,* 564

Soluble tumor necrosis factor receptor type II, production, in hepatitis C, 1412
Sparfloxacin
Listeria monocytogenes intracellular growth effects, 1195
resistance to, streptococci, 555
speA protein, in streptococcal toxic shock syndrome, 410
Specific granules, neutrophil, YKL-40 protein, in pneumonia, 1722
Spleen
apoptosis in, induction by *Trypanosoma cruzi trans*-sialidase, mouse model, 1398
enlargement, in schistosomiasis, 1298
Spontaneous bacterial peritonitis, treatment, cephalosporins, 1597
Spores, *Bacillus*, decontamination, antimicrobial nanoemulsions for, mouse model, 1939
Spotted fever, epidemiology, North Carolina, 900
Squalene emulsion (MF59) adjuvant, in cytomegalovirus vaccine, 970
Squamous intraepithelial lesions, cervical, human papillomavirus seroreactivity in, 1424
Staphylococci, coagulase-negative, sepsis, vs. tumor necrosis factor–α levels, 116
Staphylococcus aureus
bacteremia, emerging pathogen monitoring and, 87
endocarditis, rabbit model, 1561
enterotoxin, in vaccination, mouse model, 1370
nasal carriage, in human immunodeficiency virus infection, eradication, 896
osteomyelitis, pathogenesis, mouse model, 1912
resistance in, trimethoprim-sulfamethoxazole, 1809
sepsis, vs. tumor necrosis factor–α levels, 116
superantigens, crossreactive antibodies to, mouse model, 1365
vaccination, mouse model, 1365, 1370
Stavudine, for human immunodeficiency virus infection
$CD8^+$ anti–human immunodeficiency virus suppressor activity, 68
clinical trials, 351
hepatitis C viremia and, 574
Stibogluconate, for cutaneous leishmaniasis, 1735
Streptococci
group A (*Streptococcus pyogenes*)
host defenses against, 1718
infections, risk for invasiveness, 410
M-1 strain, opsonophagocytosis susceptibility, 1921
group B, vaccination, rabbit model, 892
sepsis, vs. tumor necrosis factor–α levels, 116
viridans, resistance in, transfer, 555
Streptococcus mitis, resistance in, transfer, 555
Streptococcus pneumoniae (*See* Pneumococci [*Streptococcus pneumoniae*])
Streptococcus pyogenes (*See* Streptococci, group A [*Streptococcus pyogenes*])
Stromal-derived factor 1 chemokine, polymorphism, in human immunodeficiency virus infection, 285
Sulfamethoxazole, resistance to, *Pneumocystis carinii*, 1969
Superantigens
Staphylococcus aureus, crossreactive antibodies to, mouse model, 1365
Yersinia pseudotuberculosis, colonic epithelial pathophysiology and, mouse model, 1590
Superoxide, deficiency, in human immunodeficiency virus infection, 206
Surfactant proteins, binding to respiratory syncytial virus fusion glycoprotein, 2009
Surfactants, in antimicrobial nanoemulsions, for *Bacillus* decontamination, mouse model, 1939
Susceptibility testing, pneumococci, multiresistant, 1577
Syphilis
in archaeologic skeletal specimen, 2060
epidemiology, jailed women in New York, 1159
genital ulcers in
testing for, 1382
treatment, 1886
Systemic lupus erythematosus
BK virus infections in, 1
JC virus infections in, 1
TT viremia in, 838

T cells
amphotericin B inhibition, *Listeria monocytogenes* acquired immunity and, mouse model, 1186
in *Aspergillus fumigatus* pulmonary infections, mouse model, 1957
CD4
as cytomegalovirus infection indicator, in kidney transplantation, 195
in human immunodeficiency virus infection (*See* Human immunodeficiency virus infection [type 1 or unspecified], T cells in)
sequestration, in tuberculosis, 225
CD8
anti–human immunodeficiency virus suppressor activity, in human immunodeficiency virus infection, 68
as cytomegalovirus infection indicator, in kidney transplantation, 195
in dengue hemorrhagic fever, in pediatric patients, 1429
in feline immunodeficiency virus, L-selectin–negative, 1503
influenza-specific, interleukin-12 enhancement, 1477
response to canarypox-based human immunodeficiency virus vaccine, 290
CD40, in tuberculosis resistance, 141
CD69, in dengue hemorrhagic fever, in pediatric patients, 1429
cytotoxic
cytomegalovirus response, in kidney transplantation, 247
in human immunodeficiency virus infection
combination antiretroviral agent effects on, 359
in repeated exposure without seroconversion, 1406
influenza-specific, interleukin-12 enhancement, 1477
in simian immunodeficiency virus, nonprogressive, 1133
in feline immunodeficiency virus, L-selectin–negative, 1503
helper, response
to cytomegalovirus, in kidney transplantation, 247
to inactivated influenza virus, mouse model, 579
in leishmaniasis, 1731
in hepatitis C, 1412
in human immunodeficiency virus infection (*See* Human immunodeficiency virus infection [type 1 or unspecified], T cells in)
interferon-τ production in, in tuberculosis, 2069
in Kawasaki disease, 1869
memory, influenza-specific, interleukin-12 enhancement, 1477
phenotypically activated τδ, in tuberculosis resistance, 141
phosphoantigen-reactive, in human immunodeficiency virus replication suppression, 858
proliferation of, in hepatitis B vaccination, 15
reconstitution, in highly active antiretroviral therapy, for human immunodeficiency virus infection, 76
response
to cytomegalovirus, in kidney transplantation, 247
to *Haemophilus influenzae* mucosal immunization, mouse model, 122

to malaria vaccine, 1656
to *Neisseria gonorrhoeae* porin, 762
in simian immunodeficiency virus, nonprogressive, 1133
Taenia solium, serologic testing for, 1307
Tafenoquine, for malaria, 1282
Tapeworm, pork, brain involvement from, serologic testing for, 1307
Technetium-99m scans, in urinary tract infections, in neonates, 904
Tetanus, vaccination (*See* Diphtheria-tetanus-pertussis vaccination)
Thalassemia, in malaria, hemoglobin levels in, 925
Thalidomide
for esophageal ulcers, in human immunodeficiency virus infection, 61
mechanism of action, 216
Thrombin-induced platelet microbicidal protein-1, in *Staphylococcus aureus* endocarditis, rabbit model, 1561
Thrombocytopenia, in infections, 176
Thrombosis, in infections, 176
Thrombotic thrombocytopenic purpura, in infections, 176
Thymidine kinase, herpes simplex virus, in drug resistance, 487
Thymus, apoptosis in, induction by *Trypanosoma cruzi trans*-sialidase, mouse model, 1398
Ticarcillin-clavulanic acid, in vancomycin-resistance promotion, 384
Tick bites, infections associated with, epidemiology, North Carolina, 900
Tissue culture, *Haemophilus influenzae*, protein D effects on, 737
Tissue factor pathway, in coagulation, 176
Toxic shock syndrome
Staphylococcus aureus, vaccination, mouse model, 1365
streptococcal, risk factors for, 410
Toxoplasmosis, in human immunodeficiency virus infection, risk, CCR5 deletion and, 920
Transforming growth factor-β, production
in malaria
cerebral, 1742
in pregnancy, 1987
in tuberculosis, 2069
Transplantation
bone marrow
cytomegalovirus neutralizing antibody in, 1747
ganciclovir-resistant cytomegalovirus infections in, in pediatric patients, 491
viral infection prophylaxis in, 571
kidney
cytomegalovirus infections in, predictive markers for, 195
hepatitis A virus vaccination in, 2014
T cell response to cytomegalovirus, 247
liver, hepatitis A virus vaccination in, 2014
microsporidiosis after, 2006
Travelers' diseases, enterotoxigenic *Escherichia coli* diarrhea
bovine hyperimmune milk product activity in, 2056
organism identification in, 2053
Treponema pallidum
identification, in archaeologic skeletal specimen, 2060
infections
epidemiology, jailed women in New York, 1159
genital ulcers in
testing for, 1382
treatment, 1886
Trichomoniasis
α-actinin detection in, 1727
epidemiology, urban adolescent females, 1624
sexually transmitted disease risk and, 1863
Trigeminal ganglion, herpes simplex virus reactivation in, mouse model, 821
Trimethoprim-sulfamethoxazole, resistance to, 1809
Pneumocystis carinii, 1969
Tropical spastic paraparesis, natural history, proviral DNA levels in, 1487
Trovafloxacin, resistance to, streptococci, 555
Trypanosoma cruzi
infections (Chagas' disease), parasite persistence in, mouse model, 480
trans-sialidase, apoptosis induction, mouse model, 1398
TT virus
detection, polymerase chain reaction for, 1748, 1750
epidemiology, 1748
infections, hepatitis C with, 27
viremia, epidemiology, Italy, 838
Tuberculosis *(See also Mycobacterium tuberculosis)*
drug resistance in
mutations in, 1751
transmission, 1608
epidemiology
multidrug-resistant, South Africa, 1608
Netherlands, 726
genetic factors in, mouse model, 150
in human immunodeficiency virus infection, immune response in, 2069
interferon-τ production in, 2069
pleural, transmesothelial monocyte migration in, 1616
resistance to, phenotypically activated $\tau\delta$ T cells in, 141
T cell sequestration in, 225
transmission
in human immunodeficiency virus infection, barhopping and, 1245
risk factors for, 726
treatment
anergy reversal in, 225
interferon-τ measurement during, 2069
Tumor necrosis factor-α
amphotericin B and, 1408
in *Candida albicans* infections, Fas-FasL interactions in, mouse model, 1648
in cerebral malaria, 1742
coagulation system effects, 176
in *Cryptococcus neoformans* infection defense, mouse model, 1637
gene polymorphism, human T cell lymphotropic virus type I uveitis susceptibility and, 880
in influenza, zanamivir effects on, 586
intrahepatic, in hepatitis C, 1704
in malaria
in anemia, 1753
pathogenesis and prognosis, 1288
in pregnancy, intrauterine growth retardation in, 1987
in *Mycobacterium avium* infections, 1230
in pneumococcal infections, in elderly persons, 551
response to lipopolysaccharide, in human immunodeficiency virus infection, 106
in sepsis and septic shock, 908
vs. microbiology, 116
in Shiga toxin interactions with brain endothelial cells, 1205
in streptococci group A defense, 1718
in tuberculosis, 2069
in *Yersinia pseudotuberculosis* mitogen stimulation, mouse model, 1590
Typhoid fever, vaccination, in epidemics, 2089

Ulcer(s)

esophageal, in human immunodeficiency virus infection
pathogenesis, 211
treatment with thalidomide, 61
genital
microbiology, 1382
treatment, 1886
peptic, *Helicobacter pylori,* in couples, 2064
Umbilical vessels, endothelial cells, Shiga toxin interactions with, 2048
Ureaplasma urealyticum, vaginal colonization, interleukin-1 receptor antagonist gene polymorphism and, 912
Urethritis, transmission, circumcision effects on, 330
Urinary tract infections
Escherichia coli
mouse model, 1374
prostatitis, virulence characteristics, 1378
interleukin-6 production in, in neonates, 904
resistance to, neutrophil recruitment in, mouse model, 1220
Urine, polyomaviruses in, in systemic lupus erythematosus, 1
Uveitis, human T cell lymphotropic virus type I, susceptibility to, tumor necrosis factor gene polymorphism and, 880

Vaccination
Ancylostoma caninum, mouse model, 1674
Bordetella pertussis (*See also* Diphtheria-tetanus-pertussis vaccination)
acellular, in adults, 397
respiratory syncytial virus response in, mouse model, 714
cholera, small bowel bacterial overgrowth and, 1709
Coccidioides immitis, 243
combination, immunologic memory induction by, 538
cytomegalovirus
canarypox-based, 843
glycoprotein B subunit, 1700
subunit, 970
diphtheria-tetanus-pertussis, *Haemophilus influenzae* vaccine with
colonization rate after, 1153
immunologic memory induction by, 538
Haemophilus influenzae
combination, avidity maturation after, 1390
in combination vaccine, 538
herd effect, Brazil, 1153
mucosal, mouse model, 122
hepatitis A virus, in transplantation, 2014
hepatitis A virus/hepatitis B virus combination, immunologic interference in, 2018
hepatitis B virus
combination, avidity maturation after, 1390
granulocyte-macrophage colony-stimulating factor with, 2023
T cell proliferative responses in, 15
hepatitis C virus, envelope protein in, 1328
hookworm, mouse model, 1674
human immunodeficiency virus
canarypox-based, 290, 1122
in pediatric patients, 626
phenotypic analysis after, 641
in pregnancy, 1080
influenza virus
age factors in, 1356
immunoglobulin subclass responses in, 1356
inactivated, T helper cell response to, mouse model, 579
nasal, mouse model, 940
malaria, immune effector mechanisms in, 1656
measles virus, dose intervals in, 187
meningococci, mouse model, 747
mucosal, *Haemophilus influenzae,* mouse model, 122
mumps virus, neurovirulence safety test, monkey model, 521
nasal
Haemophilus influenzae, mouse model, 122
interleukin-12 adjuvant for, mouse model, 940
Neisseria meningitidis
efficacy, 242
mouse model, 747
pertussis (*See also* Diphtheria-tetanus-pertussis vaccination)
acellular, in adults, 397
respiratory syncytial virus response in, mouse model, 714
pneumococcal
crossreactivity in, 1569
mouse model, 133
nonavalent conjugate, 1171
schistosomiasis, mouse model, 454
Staphylococcus aureus, mouse model, 1365, 1370
streptococci, group B, rabbit model, 892
Streptococcus pneumoniae (*See subheading* pneumococcal)
tetanus (*See* Diphtheria-tetanus-pertussis vaccination)
typhoid fever, in epidemics, 2089
Vibrio cholerae, small bowel bacterial overgrowth and, 1709
Vagina
candidiasis, macaque model, 802
colonization
interleukin-1 receptor antagonist gene polymorphisms and, 912
Lactobacillus, species identification, population demographics and, 1950
human papillomavirus in, hybrid capture assay for, 1316
microbicide for, in genital herpes prevention, mouse model, 199
microflora
human immunodeficiency virus infection transmission and, 1863
population demographics and, 1950
nonoxynol-9 preparation effects on, 426
Vaginosis, bacterial
interleukin-1 receptor antagonist gene polymorphisms and, 912
microbiology, vs. sexual behavior, 1632
sexually transmitted disease risk and, 1863
Valacyclovir
for cytomegalovirus infections, in human immunodeficiency virus infection, 695
for herpes simplex virus infections, mouse model, 594
Vancomycin
resistance to, enterococci
epidemiology, 1177
from interfacility patient transfer, 391
mouse model, 384
for *Staphylococcus aureus* endocarditis, thrombin-induced platelet microbicidal protein-1 and, rabbit model, 1561
Varicella-zoster virus, infections
acyclovir prophylaxis for, cellular immunity in, 834
zoster in, in human immunodeficiency virus infection, 1784
Vasculitis
in infections, 176
in Kawasaki disease, immune response defects in, 1869
Venezuelan hemorrhagic fever, natural history, cane mouse model, 966
Vero toxin, *Escherichia coli,* kidney pathology in, mouse model, 1374
Very late antigens, in tuberculosis resistance, 141
Vibrio cholerae, vaccination, small bowel bacterial overgrowth and, 1709
Viral infections, coagulation disorders and, 176
Virulence factors

Cryptosporidium parvum, variation among isolates, 1275
Escherichia coli, in prostatitis, 1378
measles virus, strain variation in, macaque model, 950
Mycobacterium avium, 1230
streptococci group A, 410
Visceral leishmaniasis, treatment, doxorubicin and interferon-τ for, mouse model, 811
Vitronectin receptors, on *Candida albicans*, 156
Vulvovaginal candidiasis, macaque model, 802

Waterborne diseases
microsporidiosis, in human immunodeficiency virus infection, 2006
Norwalk-like gastroenteritis, 1771
typhoid fever, vaccination, 2089
Weil's syndrome, coagulation disorders in, 176
Western blot test, for human T cell lymphotropic virus type I, in neurologic disease, 685
Whooping cough, vaccination (*See also* Diphtheria-tetanus-pertussis vaccination)
acellular, in adults, 397
respiratory syncytial virus response in, mouse model, 714
WR 238605 (tafenoquine), for malaria, 1282

Yersinia pseudotuberculosis, superantigen, colonic epithelial pathophysiology and, mouse model, 1590
YKL-40 protein, neutrophil, in pneumonia, 1722

Zanamivir, for influenza, 254, 586
Zidovudine, for human immunodeficiency virus infection, 76
advanced, 659
clinical trials, 351
with GB virus C (hepatitis G virus) infection, 1334
in neonates, 1844
pharmacokinetics, 1844
resistance to, 99, 865, 1043
viral semen loads and, 2039
in women, 1844
Zoster, epidemiology, in human immunodeficiency virus infection, 1784